Health Insurance (1995-96 Pathology Services Table) Regulations (Cth)

Case
No judgment structure available for this case.

Health Insurance (1995-96 Pathology Services Table) Regulations

Statutory Rules 1995 No. 281 as amended

made under the

Health Insurance Act 1973

This compilation was prepared on 16 July 2001

taking into account amendments up to SR 1996 No. 54

[Note: These regulations were repealed by SR 1996 No. 232]

Prepared by the Office of Legislative Drafting,

Attorney-General’s Department, Canberra

Contents

Page

  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
    1Citation

 These Regulations may be cited as the Health Insurance (1995-96 Pathology Services Table) Regulations.

2Commencement

 These Regulations commence on 28 September 1995.

3Pathology services table

The table of pathology services in the Schedule is prescribed for the purposes of subsection 4A (1) of the Health Insurance Act 1973.

4Repeal of Health Insurance (1994-1995 Pathology Services Table) Regulations

 Statutory Rules 1994 Nos. 233 and 361, and Statutory Rules 1995 Nos. 133 and 155, are repealed.

ScheduleTable of pathology services

(regulation 3)

Part1Rules of Interpretation1Interpretation of Table

 In this Table:

patient episode means:

  • (a)

    a pathology service or pathology services (other than a pathology service to which paragraph 1 (1) (b) refers) provided for a single patient whose need for the service or services was determined under subsection 16A of the Act:

    • (i)

      on the same day; or

    • (ii)

      if more than 1 test is performed on the 1 specimen within 14 days — on the same or different days;

 whether the services:

  • (iii)

    are requested by 1 or more practitioners; or

  • (iv)

    are described in a single item or in more than 1 item; or

  • (v)

    are rendered by 1 approved pathology practitioner or more than 1 pathology practitioner; or

  • (vi)

    are rendered on the same or different days; or

  • (b)

    a pathology service to which rule 4 refers that is provided in the circumstances set out in that rule that relates to the service.

recognised pathologist means a medical practitioner recognised as a specialist in pathology by a determination under section 3D or subsection 61 (3) of the Act.

serial examinations means a series of examinations requested on 1 occasion whether or not:

  • (a)

    the materials are received on different days by the approved pathology practitioner; or

  • (b)

    the examinations or cultures were requested on 1 or more request forms by the treating practitioner;

the Act means the Health Insurance Act 1973.

(2)

In these Rules, a reference to a request to an approved pathology practitioner includes a reference to a request for a pathologist-determinable service to which subsection 16A (6) of the Act applies.

(3)

A reference in this Table by number to an item that is not included in this Table is a reference to the item that has that number in the general medical services table or the diagnostic imaging services table, as the case requires.

(4)

A reference to a Group in the Table includes every item in that Group.

1ACertain pathology services to be treated as one service
  • (1)

    In this rule:

    general practitioner means a medical practitioner who:

    • (a)

      is not a consultant physician in any specialty; and

    • (b)

      is not a specialist in any specialty.

    set of pathology services means a group of pathology services:

    • (a)

      that consists of services that are described in at least 4 different items; and

    • (b)

      all of which are requested in a single patient episode; and

    • (c)

      each of which relates to a patient who is not an admitted patient of a hospital; and

    • (d)

      none of which is referred to:

      • (i)

        in item 66241, 66417, 69241, 73053 or 73055; or

      • (ii)

        in an item in Group P10 (Patient episode initiation) or Group P11 (Specimen referred).

  • (2)

    If a general practitioner requests a set of pathology services, the pathology services in the set are to be treated as individual pathology services in accordance with this rule.

  • (3)

    If the fee specified in one item that describes any of the services in the set of pathology services is higher than the fees specified in the other items that describe the services in the set:

    • (a)

      the pathology service described in the first-mentioned item is to be treated as one pathology service; and

    • (b)

      either:

      • (i)

        the pathology service in the set that is described in the item that specifies the second-highest fee is to be treated as one pathology service; or

      • (ii)

        if 2 or more items that describe any of those services specify the second-highest fee — the pathology service described in the item that specifies the second-highest fee, and that has the lowest item number, is to be treated as one pathology service; and

    • (c)

      the pathology services in the set, other than the services that are to be treated as one pathology service under paragraphs (a) and (b), are to be treated as one pathology service.

  • (4)

    If the fees specified in 2 or more items that describe any of the services in the set of pathology services are the same, and higher than the fees specified in the other items that describe the services in the set:

    • (a)

      the pathology service in the set that is described in the item that specifies the highest fee, and that has the lowest item number, is to be treated as one pathology service; and

    • (b)

      the pathology service in the set that is described in the item that specifies the highest fee, and that has the second-lowest item number, is to be treated as one pathology service; and

    • (c)

      the pathology services in the set, other than the services that are to be treated as one pathology service under paragraphs (a) and (b), are to be treated as one pathology service.

  • (5)

    If pathology services are to be treated as one pathology service under paragraph 1A (3) (c) or paragraph 1A (4) (c), the fee for the one pathology service is the highest fee specified in any of the items that describe the pathology services that are to be treated as the one pathology service.

2Precedence of items
  • (1)

    If a service is described:

    • (a)

      in an item in general terms; and

    • (b)

      in another item in specific terms;

     only the item that describes the service in specific terms applies to the service.

  • (2)

    Subject to subrule (3), if:

    • (a)

      subrule (1) does not apply; and

    • (b)

      a service is described in 2 or more items;

     only the item that provides the lower or lowest fee for the service applies to the service.

  • (3)

    If an item is expressed to include a pathology service that is described in another item, the other item does not apply to the service in addition to the first-mentioned item, whether or not the services described in the 2 items are requested separately.

3Circumstances in which services rendered following 2 requests to be taken to have been rendered following 1 request
  • (1)

    In subrule 3 (2), service includes assay, estimation and test.

  • (2)

    Two or more pathology services (other than services to which, under rule 4, this rule does not apply) rendered for a patient following 2 or more requests are taken to have been rendered following a single request if:

    • (a)

      the services are listed in the same item; and

    • (b)

      the patient’s need for the services was determined under subsection 16A (1) of the Act on the same day even if the services are rendered by an approved pathology practitioner on more than one day.

4Services to which rule 3 does not apply
  • (1)

    Rule 3 does not apply to:

    • (a)

      a pathology service described in item 66201, other than an estimation of fructosamine or lithium; or

    • (b)

      quantitative estimation, described in item 66365, of 1 or more fractions of neonatal bilirubin;

     if:

    • (c)

      the service is rendered in relation to a single specimen taken on each of not more than 4 occasions in a period of 24 hours; and

    • (d)

      the service is rendered to a patient in a hospital unit where:

      • (i)

        the presence of 1 nurse is required for each group of not more than 4 patients; and

      • (ii)

        the condition of the patients is continuously observed in relevant respects; and

    • (e)

      in order to render the service, an approved pathology practitioner who is a recognised pathologist has to arrange for a member of the laboratory staff of the approved pathology authority concerned to undertake duties in respect of the service that are in addition to the usual duties of the staff member; and

    • (f)

      the account for the service is endorsed “Rule 3 Exemption”.

  • (2)

    Rule 3 does not apply to any of the following pathology services:

    • (a)

      estimation of prothrombin time in respect of a patient undergoing anticoagulant therapy;

    • (b)

      quantitative estimation of lithium in respect of a patient undergoing lithium therapy;

    • (c)

      a service described in item 65007 in relation to a patient undergoing chemotherapy for neoplastic disease or immunosuppressant therapy;

    • (d)

      a service described in item 65007 in relation to methotrexate, gold sulfasalazine or penicillamine therapy of a patient;

    • (e)

      a service described in item 66201 in relation to methotrexate therapy of a patient;

    • (f)

      quantitative estimation of urea, creatinine and electrolytes in relation to:

      • (i)

        cis-platinum therapy of a patient; or

      • (ii)

        chronic renal failure of a patient being treated in a dialysis program conducted by a recognised hospital;

     if:

    • (g)

      under a request for a service, no more than 6 tests are requested; and

    • (h)

      the tests are performed within 6 months of the request; and

    • (i)

      the account for the service is endorsed “Rule 3 Exemption”.

  • (3)

    Rule 3 does not apply to a pathology service:

    • (a)

      to which item 66221 applies; and

    • (b)

      for which a specimen is collected on each of 3 days for the purpose of making a valid estimation; and

    • (c)

      for which the account is endorsed “Rule 3 Exemption”.

5Item taken to refer only to the first service of a particular kind

 For the purposes of an item in Group P1 (Haematology):

  • (a)

    if pathology services of a kind referred to in item 65017 or 65019 are rendered for a patient during a period when the patient is in hospital, the item applies only to the first pathology service of that kind rendered for the patient during that period; and

  • (b)

    if:

    • (i)

      tests (except tests mentioned in item 65023) are carried out in relation to a patient episode; and

    • (ii)

      specimen material from the patient episode is stored; and

    • (iii)

      in response to a request made within 14 days of the patient episode, further tests (except tests mentioned in item 65023) are carried out on the stored material;

 the later tests and the earlier tests are taken to be part of one patient episode.

6Certain items not to apply to a service referred by one pathology practitioner to another
  • (1)

    In this rule:

    designated pathology service means a pathology service in respect of tests relating to a single patient episode that are:

    • (a)

      tests of the kind described in item 66235; or

    • (b)

      tests of the kind described in item 66405; or

    • (c)

      tests of the kind described in item 69229.

  • (2)

    This rule applies in respect of a designated pathology service where:

    • (a)

      an approved pathology practitioner (“practitioner A”) in an approved pathology authority:

      • (i)

        has been requested to render the designated pathology service; and

      • (ii)

        is unable, because of the lack of facilities in, or expertise or experience of the staff of, the laboratory of the authority, to render 1 or more (but not all) of the tests included in the service; and

      • (iii)

        requests an approved pathology practitioner (“practitioner B”) in another approved pathology authority to render the test or tests that practitioner A is unable to render; and

      • (iv)

        renders each test included in the service, other than the test or tests in respect of which the request mentioned in subparagraph (iii) is made; and

    • (b)

      the tests mentioned in subparagraph (a) (iv) that practitioner A renders are not tests constituting a service described in item 66239, 66415 or 69239.

  • (2A)

    Where this rule applies in respect of a designated pathology service:

    • (a)

      item 66235, 66237, 66405, 66407, 66409, 66411, 66413, 69229, 69231, 69233, 69235 or 69237 (as the case requires) applies in respect of the test or tests rendered by practitioner A; and

    • (b)

      where practitioner B renders a service under a request referred to in subparagraph (2) (a) (iii) — subject to subrule (2B), the amount specified in item 66241, 66417 or 69241 (as the case requires) is payable for each test that the service comprises.

  • (2B)

    For the purposes of paragraph (2A) (b), the maximum number of tests to which item 66241, 66417 or 69241 applies is:

    • (a)

      in the case of item 66241:

      3 - X; or

    • (b)

      in the case of item 66417 or 69241:

      6 - X;

     where X is the number of tests rendered by practitioner A in relation to the designated pathology service in respect of which the request mentioned in that paragraph is made.

  • (3)

    Items in Group P10 (Patient episode initiation) do not apply to the second-mentioned approved pathology practitioner in subrule (2).

6AItems not to be split

 Except as stated in rule 6, the amount specified in an item is payable only to one approved pathology practitioner in respect of a single patient episode.

7Certain tests on stored material to be treated as part of the same patient episode

 For the purposes of items in Group P2 (Chemical):

  • (a)

    if a pathology service that involves the measurement of a substance in urine requires calculation of a substance/creatinine ratio, the service is taken to include the measurement of creatinine necessary for the calculation; and

  • (b)

    if:

    • (i)

      tests are carried out in relation to a patient episode; and

    • (ii)

      specimen material from the patient episode is stored; and

    • (iii)

      in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

 the later tests and the earlier tests are taken to be part of one patient episode.

7AItem 66317

 The amount specified in item 66317 is not payable in respect of a pathology service described in the item unless at least one of the following paragraphs applies:

  • (a)

    if the HDL cholesterol or apolipoprotein B/A1 ratio of the patient is requested to be determined because the patient has a serum cholesterol level >5.5 mmol/1 — the determination is performed on the sample that the serum cholesterol level determination for the patient was performed;

  • (b)

    if the HDL cholesterol or apolipoprotein B/A1 ratio of the patient is requested to be determined because the patient has a fasting serum triglyceride level >2.0 mmol/1 — the determination is performed on the sample that the serum triglyceride level determination for the patient was performed;

  • (c)

    the pathologist who renders the service has a written statement from the medical practitioner who requested the service that the patient is on a lipid lowering drug.

7BThyroid function testing
  • (1)

    For the purposes of item 66329:

    abnormal level of TSH means a level of TSH that is outside the normal reference range in respect of the particular method of assay used to determine the level.

  • (2)

    Except where paragraph (a) of item 66329 is satisfied, the amount specified in the item is not payable in respect of a pathology service described in the item unless the pathologist who renders the service has a written statement from the medical practitioner who requested the service that satisfies subrule (3).

  • (3)

    The written statement from the medical practitioner must indicate:

    • (a)

      that the tests are required for a particular purpose, being a purpose specified in paragraph (b) of item 66329; or

    • (b)

      that the medical practitioner who requested the tests suspects the patient has pituitary dysfunction; or

    • (c)

      that the patient is on drugs that interfere with thyroid hormone metabolism or function.

8Meaning of serial examinations or cultures

 For the purposes of an item in Group P3 (Microbiology):

  • (a)

    serial examinations or cultures means a series of examinations or cultures requested on 1 occasion whether or not:

    • (i)

      the materials are received on different days by the approved pathology practitioner; or

    • (ii)

      the examinations or cultures were requested on 1 or more request forms by the treating practitioner; and

  • (b)

    if:

    • (i)

      tests are carried out in relation to a patient episode; and

    • (ii)

      specimen material from the patient episode is stored; and

    • (iii)

      in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

 the later tests and the earlier tests are taken to be part of one patient episode.

8A
  • (1)

    A medicare benefit is not payable in respect of more than one of items 69266, 69267, 69268, 69269, 69270, 69271, 69272, 69273, 69274, 69275, 69276, 69277, 69278, 69279 and 69281 in a patient episode.

  • (2)

    For the purposes of item 69279, currently elevated transaminase level means a level of alanine aminotransferase or aspartate aminotransferase above the normal reference range in respect of the particular method of assay used to determine the level, as disclosed by a test carried out within the previous 7 days.

9Tests in Group P4 (Immunology) relating to antibodies

 For the purposes of items in Group P4 (Immunology), in items 71119, 71121, 71123 and 71125, if:

  • (a)

    tests are carried out in relation to a patient episode; and

  • (b)

    specimen material from the patient episode is stored; and

  • (c)

    in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

 the later tests and the earlier tests are taken to be part of one patient episode.

10Tests on biopsy material – AGroup P5 (Tissue Pathology) and Group P6 (Cytology)
  • (1)

    For the purposes of items in Group P5 (Tissue Pathology):

    • (a)

      biopsy material means all tissue (other than a bone marrow biopsy) received by an approved pathology practitioner from an operation, or a group of operations, performed on a patient at the same time; and

    • (b)

      if:

      • (i)

        a pathology service that comprises the examination of biopsy material is rendered under any of those items; and

      • (ii)

        a further pathology service mentioned in any of those items is also rendered using that biopsy material;

    those pathology services are taken to be 1 pathology service; and

    • (c)

      cytology means microscopic examination of 1 or more stained preparations of cells separated naturally or artificially from their normal environment by methods recognised as adequate to demonstrate their structure to a degree sufficient to enable an opinion to be formed about whether they are likely to be normal, abnormal but benign, or abnormal and malignant. In accordance with customary laboratory practice examination of a blood film and a bone marrow aspirate is excluded from this definition.

  • (2)

    For the purposes of Groups P5 and P6 of the Pathology Services Table, services in Group P6 include any services described in Group P5 on the material submitted for a test in Group P6.

  • (3)

    For the purposes of subrule 10. (2), any sample submitted for cytology from which a cell block is prepared does not qualify for a Group P5 item.

11Items in Groups P10 (Patient episode initiation) and P11 (Specimen referred) not to apply in certain circumstances
  • (1)

    For the purposes of this rule and items in Groups P10 (Patient episode initiation) and P11 (Specimen referred):

    institution means a place at which residential accommodation or day care is, or both residential accommodation and day care are, made available to:

    • (a)

      disadvantaged children; or

    • (b)

      juvenile offenders; or

    • (c)

      aged persons; or

    • (d)

      chronically ill psychiatric patients; or

    • (e)

      homeless persons; or

    • (f)

      unemployed persons; or

    • (g)

      persons suffering from alcoholism; or

    • (h)

      persons addicted to drugs; or

    • (i)

      physically or mentally handicapped persons;

     but does not include:

    • (j)

      a hospital; or

    • (k)

      a nursing home; or

    • (l)

      accommodation for aged persons that is attached to a nursing home or situated within a nursing home complex.

    licensed collection centre has the same meaning as in Part IIa of the Act.

    prescribed laboratory means a laboratory operated by:

    • (a)

      the Commonwealth; or

    • (b)

      a State or internal Territory; or

    • (c)

      an authority of a State or internal Territory; or

    • (d)

      an Australian tertiary education institution.

    specimen collection centre has the same meaning as in Part IIA of the Act.

    treating practitioner has the same meaning as in paragraph 16A (1) (a) of the Act.

  • (2)

    If a service described in an item in Group P10 or P11 is rendered by, or on behalf of, an approved pathology practitioner who is a recognised pathologist, the relevant one of those items does not apply to the service if:

    • (a)

      the service is rendered upon a request made in the course of an out-patient service at a recognised hospital; or

    • (b)

      the service is rendered upon a request made for a patient who is a private patient in a recognised hospital when the request is made; or

    • (c)

      the pathology equipment of a recognised hospital, or a prescribed laboratory, is used rendering the service; or

    • (d)

      a member of the staff of a recognised hospital, or a prescribed laboratory, participates in the service in the course of the member’s employment with the hospital or laboratory.

  • (3)

    An item in Group P10 or P11 does not apply to a pathology service to which subsection 16A (7) of the Act applies.

  • (4)

    An item in Group P10 or P11 does not apply to a pathology service unless at least one item in Groups P1 to P8 also applies to that service.

  • (5)

    Subject to subrule (7), if one item in Group P10 applies to a patient episode, no other item in that Group applies to that patient episode.

  • (6)

    An item in Group P11 applies only to the approved pathology practitioner or approved pathology authority to whom the specimen mentioned in the item was referred.

  • (7)

    If, in respect of the same patient episode:

    • (a)

      services referred to in 1 or more items in Group P5 and one or more of Groups P1, P2, P3, P4, P6, P7 and P8 are rendered by an approved pathology practitioner in the laboratory of another approved pathology authority; and

    • (b)

      services referred to in 1 or more items in Group P6 and one or more of Groups P1, P2, P3, P4, P5, P7 and P8 are rendered by another approved pathology practitioner in another approved pathology authority;

     the fee specified in the applicable item in Group P10 is payable to both approved pathology practitioners.

  • (8)

    If more than one specimen is collected from a person on the same day for the provision of pathology services:

    • (a)

      in accordance with more than one request; and

    • (b)

      in or by a single approved pathology authority;

     only a single amount specified in the applicable item in Group P10 is payable for the services.

  • (9)

    The amount specified in item 73921 is payable only once in respect of a single patient episode.

12Application of an item in Group P11 (Specimen referred) to a service excludes certain other items

 If item 73921 applies to a patient episode, none of the items in Group P10 applies to any pathology service rendered by the approved pathology authority or approved pathology provider who claimed item 73921 in respect of that patient episode.

13Circumstances in which an item in Group P11 (Specimen referred) does not apply
  • (1)

    An item in Group P11 does not apply to a referral if:

    • (a)

      a service in respect of the same patient episode has been carried out by the referring approved pathology authority; and

    • (b)

      the approved pathology authority to which the referral is made is related to the referring approved pathology authority.

  • (2)

    An approved pathology authority is related to another approved pathology authority for the purposes of subclause (1) if:

    • (a)

      both approved pathology authorities are employed (including employed under contract) by the same person, whether or not that person is also an approved pathology authority; or

    • (b)

      either of the approved pathology authorities is employed (including employed under contract) by the other; or

    • (c)

      if both of the approved pathology authorities are corporations — the approved pathology authorities are related corporations within the meaning of the Corporations Law; or

    • (d)

      the approved pathology authorities are partners (whether or not either or both of the approved pathology authorities are individuals and whether or not other persons are in partnership with either or both of the approved pathology authorities).

14Abbreviations
  • (1)

    The abbreviations in Part 3 of this Table may be used to identify particular pathology services or groups of pathology services.

  • (2)

    The names of services not listed in Part 3 of this Table must be written in full.

Part2Services and fees

Item

Pathology service

Fee  ($)

Group P1 — Haematology

65001

Erythrocyte count, C-reactive protein, erythrocyte sedimentation rate, blood viscosity, haematocrit, haemoglobin, platelet count, leucocyte count, or reticulocyte count — 1 or 2 tests

5.65

65003

3 or more tests described in item 65001, and calculation or measurement of cell index or indices

7.75

65005

Examination of blood film, or 5 part differential cell count, or both 5 part differential cell count and examination of blood film, including (if performed):

(a) a service described in item 65027; and

(b) any of the following services:

  • (i)

    examination of blood film by special stains to demonstrate Heinz bodies, parasites or iron;

  • (ii)

    examination of a blood film with alpha-naphthyl acetate esterase, chloroacetate esterase, neutrophil alkaline phosphatase, nitroblue tetrazolium, periodic acid Schiff or Sudan Black stains;

  • (iii)

    Kleihauer test for HbF on blood film

10.25

65007

Full blood examination (consisting of the services described in items 65003 and 65005)

17.20

65009

Haemolysis or metabolic enzymes — assessment by:

(a) erythrocyte autohaemolysis test;

(b) erythrocyte fragility test;

(c) sugar water test;

(d) erythrocyte metabolic enzyme test;

(e) heat denaturation test;

(f) isopropanol precipitation test;

(g) acid haemolysis test; and

(h) quantitation of muramidase in serum or urine;

1 or more tests

33.30

65011

Haemoglobinopathy, tests for the diagnosis of, consisting of haemoglobin electrophoresis and 2 of:

(a) examination for HbH; or

(b) quantitation of HbA2; or

(c) quantitation of HbF;

including a service described in item 65001, 65003, 65005 or 65007 (if performed)

52.80

65013

Bone marrow trephine biopsy — histopathological examination of sections of bone marrow, including (if performed):

(a) examination of aspirated material; and

(b) special stains or immunochemical techniques (if any); and

(c) a service described in item 65001, 65003, 65005, 65007 or 65015

133.70

65015

Bone marrow — examination of aspirated material (including clot sections where necessary), including (if performed):

(a) special stains or immunochemical techniques (if any); and

(b) a service described in item 65001, 65003, 65005 or 65007

82.00

65017

Blood grouping (including back-grouping if performed) — AABO and Rh (D antigen)

9.90

65019

Blood grouping — Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system — 1 or more systems, including a service described in item 65017 (if performed)

19.75

65021

Blood grouping (including back-grouping if performed), and examination of serum for Rh and other blood group antibodies, including:

(a) identification and quantitation of any antibodies detected; and

(b) (if performed) a service described in item 65001, 65003, 65005 or 65007

36.75

65023

Compatibility tests — all tests performed on any 1 day, including:

(a) all grouping checks of patient and donor; and

(b) examination for antibodies, and, if necessary, quantitation of any antibodies detected; and

(c) a service described in item 65001, 65003, 65005, 65007, 65017 or 65021 (if performed)

99.75

65025

Examination of serum for blood group antibodies (including identification and, if necessary, quantitation of any antibodies detected)

20.80

65027

1 or more of the following tests:

(a) direct Coombs test;

(b) qualitative or quantitative test for cold agglutinins or heterophile antibodies;

(c) qualitative spectroscopic examination of blood for abnormal haemoglobins;

(d) qualitative test for red cell porphyrins and detection of metalbumin (Schumm’s test)

8.95

65029

Skin bleeding time, coagulation time, prothrombin time, activated partial thromboplastin time, thrombin time (including test for presence of an inhibitor and serial tests for fibrinolysis), test for factor XIII deficiency, fibrinogen, or 1 of: fibrinogen degradation products, fibrin monomer or D-dimer — 1 test

12.40

65031

2 tests described in item 65029

16.40

65033

3 tests described in item 65029

20.40

65035

4 or more tests described in item 65029

24.40

65037

Quantitation, by 1 or more techniques, of: plasminogen, antithrombin III, Protein C, Protein S, heparin cofactor II euglobulin clot lysis time and test for lupus anticoagulant — 1 to 3 tests

35.80

65039

4 or more tests described in item 65037

80.80

65041

Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or similar substance — 1 or more tests

55.80

65043

Heparin quantitation when monitoring a patient on subcutaneous heparin or low molecular weight heparin — 1 or more tests

32.50

65045

Quantitation of Von Willebrand’s factor antigen (factor VIII related antigen), Von Willebrand’s factor (ristocetin cofactor), factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, or Passovy factor — 1 tests

48.80

65047

2 tests described in item 65045

95.80

65049

3 or more tests described in item 65045

140.80

Group P2 — Chemical

66201

Quantitation in serum, plasma, urine or other body fluid, by any method except reagent tablet or reagent strip (with or without reflectance meter or electrophoresis) of:

  alanine aminotransferase, albumin, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total), bilirubin (any fractions), calcium (total, dialysed or ionised), chloride, creatine kinase, creatine kinase isoenzymes (if not performed as described in item 66249), creatinine, fructosamine, gamma glutamyl transpeptidase, globulin, glucose, lactate dehydrogenase, lipase, lithium, magnesium, phosphate, potassium, total protein, sodium, urate or urea — 1 test

9.55

66203

2 tests described in item 66201

11.60

66205

3 tests described in item 66201

13.65

66207

4 tests described in item 66201

15.70

66209

5 tests described in item 66201

17.75

66211

6 or more tests described in item 66201

19.80

66213

Test by any method (except reagent strip or dip-stick):

(a) for the presence of:

  • (i)

    the following urine constituents — Abilirubin, cystine (cysteine), haemoglobin, melanin (melanogen), myoglobin, porphobilinogen, porphyrins, urobilinogen; or

  • (ii)

    cryoglobulins or cryofibrinogen in plasma; or

(b) of pH of body fluids other than urine (not including urine acidification test);

1 or more tests

13.00

66215

Quantitation of cryoglobulins or cryofibrinogen following their detection in a test described in item 66213, including that service — 1 or more tests

20.45

66223

Osmolality, estimation by osmometer, in serum or in urine — 1 or more tests

24.35

66225

Quantitation of:

(a) blood gases (including pO2, oxygen saturation and pCO2); and

(b) bicarbonate and pH;

including any other measurement (e.g., haemoglobin or potassium) or calculation performed on the same specimen — 1 or more tests on 1 specimen

33.25

66227

Quantitation of blood gases, bicarbonate and pH as described in item 66225 on each specimen in excess of 1 to a maximum of 6 specimens within any 1 day

8.80

66229

Calculus, analysis of 1 or more

30.20

66231

All qualitative and quantitative tests on blood, urine or other body fluid for:

(a) a drug or drugs of abuse (including illegal drugs and legally available drugs taken other than in appropriate dosage); or

(b) ingested or absorbed toxic chemicals;

including a service described in item 66235, 66237 or 66239 (if performed), but excluding:

(c) the surveillance of sports people and athletes for performance improving substances; and

(d) the monitoring of patients participating in a drug abuse treatment program

41.00

66235

Quantitation, not elsewhere described in this Table by any method or methods, in blood or other body fluid, of a drug being used therapeutically by the patient from whom the specimen was taken — 1 test

(Item is subject to rule 6)

20.45

66237

2 tests described in item 66235

(Item is subject to rule 6)

28.65

66239

3 or more tests described in item 66235

36.85

66241

Tests described in item 66235, if rendered under a request referred to in subparagraph (2) (a) (iii) of rule 6 — Aeach test to a maximum of 2 tests

(Item is subject to rule 6)

8.20.

66243

Amniotic fluid, spectrophotometric examination of, and quantitation of:

(a) lecithin/sphingomyelin ratio; or

(b) palmitic acid, phosphatidylglycerol or lamellar body phospholipid;

1 or more tests

32.50

66247

Electrophoresis

(including quantitation), of serum and either or both urine or other body fluid all collected within a 28 day period, to demonstrate protein classes or presence of paraprotein, including the preliminary quantitation of:

(a) total protein, albumin and globulin; or

(b) total relevant enzyme activity;

2 or more tests

49.85

66249

Electrophoresis, quantitative or qualitative, of serum, urine or other body fluid to demonstrate:

(a) protein classes; or

(b) presence and amount of paraprotein; or

(c) the isoenzymes of lactate dehydrogenase, alkaline phosphatase and creatine kinase;

including the preliminary quantitation of total protein, albumin and globulin or of total relevant enzyme activity

35.20

66250

Electrophoresis, quantitation or qualitative, of serum, for demonstration of lipoprotein subclasses, if the cholesterol is

 >6.5 mmol/l and triglyceride >3.0 mmol/l or in the diagnosis of types III and IV hyperlipidaemia — each episode to a maximum of 2 episodes in a 12 month period

30.20

66255

Alpha-1-acid glycoprotein, alpha-1-antitrypsin, or alpha-2-macroglobulin — quantitation in serum, urine or other body fluid — 1 or more tests

19.90

66257

C-1 esterase inhibitor — Aquantitation

19.90

66258

C-1 esterase inhibitor — functional assay

44.50

66261

CA-125 antigen, CA-15.3 antigen, CA-19.9 antigen, carcinoembryonic antigen (CEA), mammary serum antigen, mucin-like carcinoma-associated antigen (1 or more fractions), neuron-specific enolase, or thyroglobulin in serum or other body fluid, in the monitoring or confirmation of malignancy — quantitation — 1 test

19.90

66262

2 or more tests described in item 66261

36.65

66263

Iron studies, consisting of quantitation of:

(a) serum iron;

(b) transferrin or iron binding capacity; and

(c) ferriti

36.70

66265

Serum B12 or serum folate — 1 or more tests within a 28-day period

24.35

66267

Red cell folate and serum B12, and, if required, serum folate, to a maximum of 3 episodes in a 12-month period

44.45

66269

Vitamins — quantitation of vitamins A, B1, B2, B3, B6, C, and E in blood, urine or other body fluid — 1 or more tests within a 6-month period

30.20

66271

Vitamin D or D fractions — 1 or more tests

37.90

66277

Quantitation of aluminium (except if item 66325 applies), arsenic, beryllium, cadmium, copper, chromium, gold, manganese, mercury, nickel, selenium, or strontium, in blood, urine or other body fluid or tissue — 1 or more tests in a 6-month period

35.35

66279

Blood lead quantitation (other than for occupational health screening purposes) to a maximum of 3 tests in a 6 — month period — each test

30.20

66281

Porphyrins (1 or more fractions), catecholamines (1 or more fractions), hydroxymethoxymandelic acid (HMMA), homovanillic acid (HVA), metanephrines, methoxyhydroxyphenylethylene glycol (MHPG), or phenylacetic acid (PAA) — quantitation — 1 or more tests

39.45

66283

Quantitation of:

(a) faecal fat; or

(b) breath hydrogen in response to loading with disaccharides;

1 or more tests within a 28-day period

39.45

66285

Enzymes — quantitation of 1 or 2 in solid tissue or tissues other than blood elements

39.45

66287

Quantitation of 3 to 5 enzymes as described in item 66285

73.45

66289

Quantitation of 6 or more enzymes as described in item 66285

97.45

66293

Thyrotrophin releasing hormone (TRH) test, including provision and administration of TRH and quantitation of hormones

54.50

66295

Personal performance by a recognised pathologist of 1 or more of the following:

(a) growth hormone suppression by glucose loading;

(b) growth hormone stimulation by exercise;

(c) dexamethasone suppression test;

(d) L-dopa stimulation of growth hormone

25.80

66297

Personal performance by a recognised pathologist of 1 of the following:

(a) gonadotrophin releasing hormone stimulation test;

(b) synacthen stimulation test;

(c) glucagon stimulation test with C-peptide measurement;

(d) pentagastrin stimulation of thyrocalcitonin release;

(e) secretin stimulation of gastrin release;

(f) insulin hypoglycaemia;

(g) arginine infusion

54.50

66299

Personal performance by a recognised pathologist of 2 or more tests described in item 66297

87.70

66315

Quantitation of hormone receptors on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast — 1 or more tests

78.90

66317

Quantitation of HDL cholesterol or apolipoprotein B/A1 ratio in a patient who:

(a) has a serum cholesterol level >5.5 mmol/1; or

(b) has a fasting serum triglyceride level >2.0 mmol/1; or

(c) is on a lipid lowering drug prescribed by a medical practitioner;

each episode to a maximum of 4 episodes in a 12 month period

(Item is subject to rule 7A)

12.35

66319

Quantitation of glycosylated haemoglobin performed in the management of established diabetes — each test to a maximum of 4 tests in a 12-month period

16.60

66321

Quantitation, in the 2nd trimester of pregnancy, of alpha fetoprotein, human chorionic gonadotrophin, oestriol and any other substance to detect foetal abnormality, including a service described in 1 or more of items 66353, 66373, 73527 and 73529 (if performed) — 1 patient episode in a pregnancy

54.50

66323

Test for tryptic activity in faeces in the investigation of diarrhoea of longer than 4 weeks duration in children under 6 years old

11.00

66325

Quantitation

 of serum aluminium in a patient in a renal dialysis program — each test

35.35

66327

TSH — quantitation, requested as a preliminary test to thyroid function testing

31.55

66329

Thyroid function tests (comprising the service described in item 66327 and 1 or more of the following tests — estimation of free thyroxine index, free thyroxine, free T3, total T3, thyroxine binding globulin) in respect of a patient, if at least one of the following conditions is satisfied:

(a) the patient has an abnormal level of TSH;

(b) the tests are performed for the purpose of:

  • (i)

    monitoring thyroid disease in the patient; or

  • (ii)

    if the patient is an admitted patient — investigating the sick euthyroid syndrome; or

  • (iii)

    investigating dementia or psychiatric illness of the patient; or

  • (iv)

    investigating amenorrhoea or infertility of the patient;

(c) the medical practitioner who requested the tests suspects the patient has pituitary dysfunction;

(d) the patient is on drugs that interfere with thyroid hormone metabolism or function

(Item is subject to rule 7B)

41.00

66331

Quantitation (except by reagent strip with or without reflectance meter or electrophoresis) of cholesterol or triglycerides or both in serum, plasma, urine or other body fluid

11.40

66335

A service described in item 66331 and 1 test described in item 66201

13.65

66337

A service described in item 66331 and 2 tests described in item 66201

15.70

66339

A service described in item 66331 and 3 tests described in item 66201

17.75

66341

A service described in item 66331 and 4 or more tests described in item 66201

19.80

66343

Detection or quantitation or both (not including the detection of nicotine and metabolites in smoking withdrawal programs) of a drug, or drugs, of abuse or a therapeutic drug, on a sample collected from a patient:

(a) participating in a drug abuse treatment program; or

(b) being treated for drug effects;

including all tests on blood, urine or other body fluid — each episode, to a maximum of 21 episodes in a 12-month period

23.80

66353

Quantitation in serum or other body fluids of alpha fetoprotein, except if requested as part of item 66321

19.90

66355

Ferritin — quantitation, except if requested as part of iron studies

19.90

66357

Prostate specific antigen or prostatic acid phosphatase — quantitation in the confirmation

 or monitoring of malignancy — 1 test

19.90

66359

2 tests described in item 66357

36.65

66361

Beta-2-microglobulin, caeruloplasmin, haptoglobins, microalbumin in proven diabetes mellitus, or prealbumin — quantitation in serum, urine or other body fluids — 1 test

19.90

66363

2 or more tests described in item 66361

36.65

66367

Quantitation of acetoacetate, alcohol, amino acids, ammonia, angiotensin converting enzyme, beta-hydroxybutyrate, cholinesterase, cysteine, total free fatty acids, histamine, hydroxyindoleacetic acid, hydroxyproline, lactate, oxalate, pyruvate, serotonin, xylose, or zinc — 1 test

24.35

66369

2 or more tests described in item 66367

38.30

66373

Human placental lactogen or oestriol — quantitation, except if requested as part of item 66321 — 1 test

31.55

66375

2 tests described in item 66373

42.60

66405

Quantitation of hormones and hormone binding proteins — ACTH, aldosterone, androstenedione, C-peptide, calcitonin, cortisol, cyclic AMP, DHEAS, 11-deoxycortisol, dihydrotestosterone, FSH, gastrin, glucagon, growth hormone, hydroxyprogesterone, insulin, LH, oestradiol, oestrone, progesterone, prolactin, PTH, renin, sex hormone binding globulin, somatomedin C(lgF1), free or total testosterone, TSH (where not requested on its own or as part of a thyroid function test), urine steroid fraction or fractions, vasoactive intestinal peptide, vasopressin (antidiuretic hormone) — 1 test

(Item is subject to rule 6)

31.55

66407

2 tests described in item 66405(Item is subject to rule 6)

42.55

66409

3 tests described in item 66405

(Item is subject to rule 6)

53.55

66411

4 tests described in item 66405

(Item is subject to rule 6)

64.55

66413

5 tests described in item 66405

(Item is subject to rule 6)

75.55

66415

6 or more tests described in item 66405

86.55

66417

Tests described in item 66405, if rendered under a request referred to in subparagraph (2) (a) (iii) of rule 6 — each test to a maximum of 5 tests

(Item is subject to rule 6)

11.05

66419

Oral glucose tolerance test for the diagnosis of diabetes mellitus that includes the following:

(a) administration of glucose;

(b) at least 3 estimations of blood glucose;

(c) if performed, any test described in item 66405

17.70

66421

Test for reducing substances in faeces by any method (except reagent strip or dipstick)

6.50.

66422

Examination for faecal occult blood (including tests for haemoglobin and its derivatives in the faeces) by:

(a) an immunological method; and

(b) a chemical method (except reagent strip or dip stick);

with a maximum of 3 examinations on specimens collected on separate days in a 28 day period — 1 examination by both methods

8.80

66423

2 examinations by both methods described in item 66422 performed on separately collected and identified specimens

17.60

66424

3 examinations by both methods described in item 66422 performed on separately collected and identified specimens

26.40

Group P3 — Microbiology

69201

Microscopy of wet film material other than blood, from 1 or more sites, obtained directly from a patient (not cultures) including:

(a) differential cell count (if performed); or

(b) examination for dermatophytes; or

(c) dark ground illumination; or

(d) stained preparation or preparations, using any relevant stain or stains;

1 or more tests

7.35

69205

Culture and (if performed) microscopy to detect

 pathogenic micro-organisms (including fungi but excluding viruses), from nasal swabs, throat swabs, eye swabs and ear swabs, including (if performed):

(a) pathogen identification and antibiotic susceptibility testing; or

(b) the detection of antigens not elsewhere described in this Table; or

(c) a service described in item 69201;

specimens from 1 or more sites

19.35

69207

Microscopy and culture to detect pathogenic micro-organisms, including fungi but excluding viruses, from:

(a) skin or other superficial sites, urethra, vagina, cervix or rectum (except for faecal pathogens); or

(b) specimens of sputum (except when part of item 69213);

including (if performed):

(c) the detection of antigens not elsewhere specified in this Table; or

(d) pathogenic identification and antibiotic susceptibility testing; or

(e) a service described in items 69201, 69205 and 73810;

1 or more tests on 1 or more specimens

28.25

69209

Microscopy and culture of postoperative wounds, aspirates of body cavities, synovial fluid, CSF or operative or biopsy specimens, for the presence of pathogenic micro-organisms (including fungi but excluding viruses) involving aerobic and anaerobic culture and the use of different culture media, and including (if performed):

(a) pathogen identification and antibiotic susceptibility testing;

(b) the detection of antigens not elsewhere specified in this Table; or

(c) a service described in item 69201, 69205 or 69207;

specimens from 1 or more sites

38.30

69213

Microscopy with appropriate stains and culture of 3 specimens of sputum, urine or other body fluids for mycobacteria including (if performed):

(a) microscopy and culture of other bacterial pathogens; or

(b) pathogen identification and antibiotic susceptibility testing; and

(c) a service described in item 69201

99.35

69217

Urine examination (including serial examination) by any means other than simple culture by dip slide, including:

(a) cell count; and

(b) culture; and

(c) colony count (if performed); and

(d) stained preparations; and

(e) identification of cultured pathogens; and

(f) antibiotic susceptibility testing; and

(g) any examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts

20.55

69219

Detection of:

(a) the antigens of Haemophilus influenzae, Streptococcus pneumoniae, Neisseria, meningitidis, Group B streptococcus respiratory syncytial virus, cryptococcal antigens or Varicella zoster; or

(b) Clostridium difficile toxin (except if the service described in item 69211 has been performed);

1 or more tests

16.25

69223

Detection of herpes simplex virus from material obtained directly from a patient (not cultures) — 1 or more tests

9.70

69229

Quantitation of 1 antibody to microbial or exogenous antigens not elsewhere described in the Schedule — 1 test

(Item is subject to rule 6)

13.90

69231

2 tests described in item 69229

(Item is subject to rule 6)

24.70

69233

3 tests described in item 69229

(Item is subject to rule 6)

34.70

69235

4 tests described in item 69229

(Item is subject to rule 6)

44.70

69237

5 tests described in item 69229

(Item is subject to rule 6)

54.70

69239

6 or more tests described in item 69229

64.70

69241

Tests described in item 69229, if rendered under a request referred to in subparagraph (2) (a) (iii) of rule 6 — each test to a maximum of 5 tests

(Item is subject to rule 6)

10.80

69251

Antibiotics or antimicrobial chemotherapeutic agents in serum, urine or other body fluid — quantitation — 1 or more tests

24.35

69253

Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including:

(a) immune status, specific syphilis serology, hepatitis B surface antigen; and

(b) a service described in 1 or more of items 69229, 69243 and 69245 (if performed)

13.90

69255

Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including:

(a) the determination of 2 of the following: rubella immune status, specific syphilis serology or hepatitis B surface antigen;

(b) a service described in 1 or more of items 69229, 69243 and 69245 (if performed)

24.70

69257

Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including:

(a) the determination of all 3 of the following: rubella immune status, specific syphilis serology and hepatitis B surface antigen); and

(b) a service described in 1 or more of items 69229, 69243 and 69245 (if performed)

34.70

69262

Detection of Chlamydia by any method in specimens from 1 or more sites

19.85

69264

Examination for Herpes simplex virus of 1 or more types by culture in material obtained directly from a patient, including a service described in items 69223, 69262 or 69282 (if performed)

28.20

69266

Investigation for acute Hepatitis A — Hepatitis A IgM antibody test

(Item is subject to rule 8A)

13.90

69267

Determination of immune status to Hepatitis A — Hepatitis A IgG antibody test

(Item is subject to rule 8A)

13.90

69268

Investigation for acute or resolving Hepatitis B, including:

(a) Hepatitis B surface antigen test; and

(b) Hepatitis B core antibody test; and

(c) Hepatitis B e antibody test (if the Hepatitis B surface antigen test is negative and Hepatitis B core antibody test is positive) (if performed)

(Item is subject to rule 8A)

24.70

69269

Investigation for resolving Hepatitis B if Hepatitis B core antibody test is positive and Hepatitis B surface antigen test is negative, including:

(a) Hepatitis B surface antigen test; and

(b) Hepatitis B core antibody test; and

(c) Hepatitis B surface antibody test

(Item is subject to rule 8A)

34.70

69270

Determination of immune status to Hepatitis B (post exposure) — Hepatitis B core antibody test

(Item is subject to rule 8A)

13.90

69271

Determination of immune status to Hepatitis B (post vaccination) — Hepatitis B surface antibody test

(Item is subject to rule 8A)

13.90

69272

Investigation for chronic Hepatitis B or determination of carriage of Hepatitis B antigen — Hepatitis B surface antigen test

(Item is subject to rule 8A)

13.90

69273

Investigation for chronic Hepatitis B or carriage of Hepatitis B antigen if the Hepatitis B surface antigen test is positive, including:

(a) Hepatitis B surface antigen test; and

(b) Hepatitis B e antigen test

(Item is subject to rule 8A)

24.70

69274

Investigation for Hepatitis C — Hepatitis C antibody test

(Item is subject to rule 8A)

13.90

69275

Investigation for acute or chronic Hepatitis D in a patient with a positive Hepatitis B surface antigen test — Hepatitis D antibody test

(Item is subject to rule 8A)

13.90

69276

Determination of immune status to Hepatitis A and Hepatitis B, including:

(a) Hepatitis A IgG antibody test; and

(b) Hepatitis B core antibody test or Hepatitis B surface antibody test

(Item is subject to rule 8A)

24.70

69277

Investigation for chronic viral hepatitis,

 including:

(a) Hepatitis B surface antigen test; and

(b) Hepatitis C antibody test

(Item is subject to rule 8A)

24.70

69278

Investigation for chronic viral hepatitis if

 Hepatitis B surface antigen test is positive, including:

(a) Hepatitis C antibody test; and

(b) Hepatitis B surface antigen test; and

(c) Hepatitis B e antigen test

(Item is subject to rule 8A)

34.70

69279

Investigation for acute Hepatitis A, Hepatitis B or Hepatitis C in a patient with a currently elevated transaminase level, including:

(a) Hepatitis A IgM antibody test; and

(b) Hepatitis C antibody test; and

(c) Hepatitis B surface antigen test; and

(d) Hepatitis B core antibody test; and

(e) Hepatitis B e antibody test (if Hepatitis B surface antigen test is negative and Hepatitis B core antibody test is positive) (if performed)

(Item is subject to rule 8A)

44.70

69281

Syphilis serology and any 1 of items 69273, 69274 or 69277

(Item is subject to rule 8A)

34.70

69282

Microscopy and culture to detect pathogenic micro-organisms, including the detection of Chlamydia by any method from urethra, vagina, cervix or rectum and including (if performed):

(a) the detection of microbial antigens; or

(b) pathogen identification and antibiotic susceptibility testing; or

(c) a service described in item 69201, 69205, 69207, 69223, 69262, 69264 or 73810;

1 or more tests on 1 or more specimens

48.10

69285

Microscopy of faeces for parasites using concentration techniques (including the use of

  appropriate stains) with a maximum of 3 examinations on specimens collected on separate days, including a service (if performed) described in item 69201 — 1 examination

16.20

69286

2 examinations described in item 69285 performed on separately collected and identified specimens

32.40

69287

3 examinations described in item 69285 performed on separately collected and identified specimens

48.60

69289

Culture of faeces for faecal pathogens, using at least 2 selective or enrichment media and culture in at least 2 different atmospheres including (if performed):

(a) pathogen identification and antibiotic susceptibility testing; and

(b) the detection of clostridial toxins or antigens not elsewhere specified in this Table; and

(c) a service described in item 69201;

with a maximum of 3 examinations performed on separately collected and identified specimens in any 7 day period — 1 examination

46.45

69290

2 examinations described in item 69289 performed on separately collected and identified specimens

92.90

69291

3 examinations described in item 69289 performed on separately collected and identified specimens

139.35

69293

Blood culture for pathogenic micro-organisms (other than viruses), including sub-cultures and (if performed):

(a) identification of any cultured pathogen; and

(b) necessary antibiotic susceptibility testing;

to a maximum of 3 sets of cultures — 1 set of cultures

20.80

69294

2 sets of cultures described in item 69293

41.60

69295

3 sets of cultures described in item 69293

62.40

Group P4 — Immunology

71061

Immunoelectrophoresis or immunofixation, of serum, urine or other body fluid, and characterisation of, a paraprotein or cryoglobulin not previously characterised, including a service described in 1 or both of items 66213 and 66215 (if performed) — 1 or more tests

28.80

71063

Immunoelectrophoresis or immunofixation of serum and urine concurrently collected, and characterisation of, a paraprotein not previously characterised — 2 or more tests

43.45

71065

Examination of CSF and serum concurrently collected for the presence of oligoclonal proteins — 2 or more tests

43.45

71067

Quantitation of total immunoglobulins A, G, M or D by any method in serum, urine or other body fluid — 1 test

14.85

71069

2 tests described in item 71067

23.45

71071

3 or more tests described in item 71067

32.05

71073

Quantitation of all 4

  immunoglobulin G subclasses, with a maximum of 2 patient episodes in a 12-month period — each patient episode

104.75

71075

Quantitation of immunoglobulin E (total), with a maximum of 2 patient episodes in a 12-month period — each patient episode

26.70

71077

Quantitation of immunoglobulin E (total) in the follow-up of a patient with proven immunoglobulin-E-secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis, with a maximum of 6 patient episodes in a 12-month period — each patient episode

26.70

71079

Detection of specific immunoglobulin G or E antibodies to single or multiple potential allergens, with a maximum of 4 patient episodes in a 12 month period — each patient episode

24.10

71081

Quantitation of total haemolytic complement

19.90

71083

Quantitation of complement components C3 and C4 or properdin factor B — 1 test

19.90

71085

2 tests described in item 71083

28.55

71087

3 or more tests described in item 71083

37.20

71089

Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this Schedule — 1 test

28.75

71091

2 tests described in item 71089

52.10

71093

3 or more tests described in item 71089

75.45

71097

Antinuclear antibodies — detection in serum or other body fluids, including quantitation if required

25.10

71099

Double-stranded DNA antibodies — quantitation by 1 or more methods other than the Crithidia method

26.20

71101

Antibodies to 1 or more extractable nuclear antigens — detection in serum or other body fluids

17.15

71103

Characterisation of an antibody detected in a service described in item 71101 (including that service)

51.35

71106

Rheumatoid factor — detection by any technique in serum or other body fluids, including quantitation if required

11.15

71109

Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, cardiolipin, glomerular basement membrane, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, neutrophil cytoplasm, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor) — detection, including quantitation if required,

 of 1 antibody

34.10

71113

Detection of 2 antibodies described in item 71109

46.80

71115

Detection of 3 antibodies described in item 71109

59.50

71117

Detection of 4 antibodies described in item 71109

72.20

71119

Antibodies to tissue antigens not elsewhere specified in this Table — detection, including quantitation if required, of 1 antibody

17.10

71121

Detection of 2 antibodies specified in item 71119

20.50

71123

Detection of 3 antibodies specified in item 71119

23.90

71125

Detection of 4 or more antibodies specified in item 71119

27.30

71127

Functional tests for lymphocytes — quantitation other than by microscopy of:

(a) proliferation induced by 1 or more mitogens; or

(b) proliferation induced by 1 or more antigens; or

(c) estimation of 1 or more mixed lymphocyte reactions;including a test described in item 65005 (if performed), with a maximum of 2 patient episodes in a 12-month period — each patient episode

174.05

71129

2 tests described in item 711272

15.00

71131

3 or more tests described in item 711272

55.95

71135

Quantitation of neutrophil function, comprising at least 2 of the following:

(a) chemotaxis;

(b) phagocytosis;

(c) oxidative metabolism;

(d) bactericidal activity;including any test described in item 65005 (other than nitroblue tetrazolium reduction slide test), with a maximum of 2 patient episodes in a 12-month period — each patient episode

205.25

71137

Quantitation of cell-mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7 antigens, with a maximum of 2 patient episodes in a 12-month period — each patient episode

29.85

71139

Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations, including a total lymphocyte count by any method, on 1 or more specimens of blood, CSF or serous fluid

102.65

71141

Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on 1 or more disaggregated tissue specimens

194.80

71143

Characterisation (but not monitoring) of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations in an immunological or haematological malignancy, including a service described in 1 or both of items 71139 and 71141 (if performed), on a specimen of blood, CSF, serous fluid or disaggregated tissue

256.60

71145

Characterisation (but not monitoring) of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations in an immunological or haematological malignancy, including a service described in 1 or more of items 71139, 71141 and 71143 (if performed), on 2 or more specimens of disaggregated tissues or 1 specimen of disaggregated tissue and 1 or more specimens of blood, CSF or serous fluid

418.95

71147

HLA-B27 typing

32.00

71149

Complete tissue typing for 4 HLA-A and HLA-B Class I antigens (including any separation of leucocytes), including a service described in item 71147 (if performed)

106.85

71151

Tissue typing for HLA-DR, HLA-DP and HLA-DQ Class II antigens (including any separation of leucocytes) — phenotyping or genotyping of 2 or more antigens

117.30

Group P5 — Tissue pathology

72801

Examination of biopsy material (gross and microscopic) including all tissue processing, staining,

  and except as provided for in 72805 and 72807 — all professional opinions

79.05

72803

Intraoperative frozen section diagnosis of biopsy material, including any other tissue pathology service in Group P5

148.80

72805

Immunohistochemical staining of biopsy material by 1 or more labelled antibody techniques (including immunofluorescence and immunoperoxidase) and including any other tissue pathology service in Group P5

107.45

72807

Electron microscopy of biopsy material including any other tissue pathology service in Group P5

153.65

Group P6 — Cytology

73043

Cytology (including serial examinations) of nipple discharge or smears from skin, lip, mouth, nose or anus for detection of precancerous or cancerous changes — 1 or more tests

19.80

73045

Cytology (including serial examinations) for malignancy (other than an examination mentioned in item 73053); and including any Group P5 service, if performed on:

(a) specimens resulting from washings or brushings from sites not specified in item 73043; or

(b) a single specimen of sputum or urine; or

(c) 1 or more specimens of other body fluids;

1 or more tests

35.80

73047

Cytology of a series of 3 sputum or urine specimens for malignant cells

80.80

73049

Cytology material obtained directly from a patient by fine needle aspiration of solid tissue or tissues

51.75

73051

Cytology material obtained directly from a patient by fine needle aspiration of solid tissue or tissues if:

(a) the aspiration is performed by a recognised pathologist; or

(b) a recognised pathologist attends the aspiration and performs cytological examination during the attendance

88.85

73053

Cytology of smears from cervix:

(a) for detection of precancerous or cancerous changes in women with no symptoms, signs or recent history suggestive of cervical neoplasia; or

(b) due to an unsatisfactory smear taken in the circumstances defined in para (a) above;

each examination

17.80

73055

Cytology not associated with item 73053, of smears from cervix in association with:

(a) the management of previously detected abnormalities including precancerous or cancerous conditions; or

(b) the investigation of women with symptoms, signs or recent history suggestive of cervical neoplasia;

each test

17.80

73057

Cytology of smears from vagina, not associated with item 73053 or 73055 nor to monitor hormone replacement therapy — each test

17.80

Group P7 — Cytogenetics

73287

Chromosome studies including preparation, count, karyotyping and identification by banding techniques or fragile X-site determination of one or more of any tissue or fluid except blood — 1 or more tests

327.60

73289

Chromosome studies including preparation, count, karyotyping and identification by banding techniques or fragile X-site determination of blood — 1 or more tests

296.85

Group P8 — Infertility and pregnancy tests

73521

Semen examination for presence of spermatozoa, or examination of cervical mucus for spermatozoa (Huhner’s test)

6.80

73523

Semen examination (other than post-vasectomy semen examination), including:

(a) measurement of volume, sperm count, and motility; and

(b) examination of stained preparations; and

(c) morphology; and (if performed)

(d) differential count and 1 or more chemical tests;

with a maximum Of 4 Episodes In A 12-Month Period — Each EpisodE

35.80

73525

Sperm antibodies—Asperm-penetrating ability — 1 or more tests

18.20

73527

Chorionic gonadotrophin (beta-HCG) — detection

 in serum or urine by 1 or more methods, including serial dilution if performed, for diagnosis of pregnancy — 1 or more tests

9.90

73529

Chorionic gonadotrophin (beta-HCG) — quantitation in serum by 1 or more methods (except by latex, membrane, strip or other pregnancy test kit) for diagnosis of hydatidiform mole, HCG-secreting neoplasm, or threatened abortion, or follow-up of abortion or diagnosis of ectopic pregnancy, including any services performed in 73527 — 1 test

28.25

Group P9 — Simple basic pathology tests

73801

Semen examination for presence of spermatozoa

6.50

73802

Leucocyte count,

  erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count), haemoglobin, haematocrit or erythrocyte count — 1 test

4.30

73803

2 tests described in item 73802

6.00

73804

3 or more tests described in item 73802

7.70

73805

Microscopy of urine whether stained or not, or catalase test

4.30

73806

Pregnancy test by 1 or more immunochemical methods

9.90

73807

Microscopy for wet film other than urine, including any relevant stain

6.50

73808

Microscopy of Gram-stained film, including (if performed) a service described in item 73805 or 73807

8.15

73809

Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method

2.20

73810

Microscopy for fungi in skin, hair or nails — 1 or more sites

6.50

73811

Mantoux test

10.60

Group P10 — Patient episode initiation

73901

Initiation of a patient episode that consists only of a service described in item 73053, 73055 or 73057 from a person who is not in a recognised hospital or a prescribed laboratory

7.10

73903

Initiation of a patient episode that consists only of a service described in item 72801 from a person who is an in-patient of a hospital other than a recognised hospital

13.40

73905

Initiation of a patient episode that consists only of a service described in item 72801 from a person who is not an in-patient of a private hospital and not a patient of a recognised hospital

7.10

73907

Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected in a licensed collection centre

15.50

73909

Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person who is an in-patient of a hospital other than a recognised hospital

I15.50

73911

Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in the place where the personwas residing or in a nursing home or institution

9.25

73913

Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or 73907 or items in Group P9) if the specimen is collected from the person by the person

9.25

73915

Initiation of a patient episode by collection of a specimen for a service (other than a service described in items 73901, 73903 or 73905 or items in Group P9) if the specimen is collected by or on behalf of the treating practitioner

9.25

Group P11— Specimen referred

73921

Receipt of specimen by an approved pathology practitioner of an approved pathology authority from another approved pathology practitioner of a different approved pathology authority or another pathology authority

(Item is subject to subrule 11 (9))

10.00

Part3Abbreviations

Division AAbbreviations for groups of tests

Group

Tests included in group

Abbreviation

Item numbers

Cardiac enzymes

Lactate dehydrogenase (LDH), aspartate aminotransferase (AST) and creatine kinase (CK)

CE

66205

Coagulation studies

Prothrombin time, activated partial thrombo-plastin time and two or more of the following tests — bleeding time, thrombin clotting time, fibrinogen degradation products, fibrin monomer, D-dimer, factor XIII screening tests

COAG

65035

Electrolytes

Sodium (NA), potassium (K), chloride (Cl), and bicarbonate (HCO3)

E

66207

Lipid studies

Cholesterol (CHOL) and triglycerides (TRIG)

FATS

66331

Liver function tests

Alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), bilirubin (BIL), gamma glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH), and protein (PROT)

LFT

66211

Syphilis serology

Rapid plasma reagin test (RPR), or venereal disease research laboratory test (VDRL), and treponema pallidum haemagglutination test (TPHA), or fluorescent treponemal antibody-absorption test (FTA)

STS

69231

Urea, electrolytes, creatine

Urea, electrolytes, creatinine

U&E

66211

Division BAbbreviations for individual tests

Test

Abbreviation

Item

Abnormal haemoglobins

AH

65027

Acetoacetate

ACAT

66367

Acetylcholine receptor — tissue antigens — antibodies

ARA

71109

Actinomycetes — microbial antibody testing

ACT

69229

Adenovirus — microbial antibody testing

ADE

69229

Adrenal cortex — tissue antigens — antibodies

ADR

71109

Adrenocorticotrophic hormone (ACTH)

ACTH

66405

AFB microscopy and culture of sputum

AFB

69213

Alanine aminotransferase

ALT

66201

Albumin

ALB

66201

Alcohol (ethanol)

ETOH

66367

Aldosterone

ALDS

66405

Alkaline phosphatase

ALP

66201

Alkaline phosphatase — isoenzymes

ALPI

66249

Alpha fetoprotein

AFP

66353

Alpha fetoprotein — for Down’s syndrome and neural tube defect testing

NTDD

66321

Alpha-1-acid glycoprotein

AAG

66255

Alpha-1-antitrypsin

AAT

66255

Alpha-2-macroglobulin

AMG

66255

Aluminium

AL

66277

Aluminium — renal dialysis

ALR

66325

Amino acids

AA

66367

Amiodarone

AMIO

66235

Amitriptyline

AMIT

66235

Ammonia

NH3

66367

Amniotic fluid examination

AFE

66243

Amylase

AMS

66201

Amylobarb

AMYL

66235

Androstenedione

ANDR

66405

Angiotensin converting enzyme

ACE

66367

Antibiotic and antimicrobial chemotherapeutic agents — quantitation

QAA

69251

Antibodies to extractable nuclear antigens — detection

ENA

71101

Antibodies to extractable nuclear antigens — characterisation of antibodies if positive ENA

ENAP

71103

Antibodies to nuclear antigens — detection

ANA

71097

Antibodies to nuclear antigens — quantitation and measurement of DNA binding if positive ANA

ANAP

71099

Antibodies to tissue antigens — acetylcholine receptor

ARA

71109

Antibodies to tissue antigens — adrenal cortex

ADR

71109

Antibodies to tissue antigens — cardiolipin

ACL

71109

Antibodies to tissue antigens — centromere

ACA

71119

Antibodies to tissue antigens — gastric parietal cell

PCA

71119

Antibodies to tissue antigens — gliadin IgA

GLIA

71119

Antibodies to tissue antigens — glomerular basement membrane

GBA

71109

Antibodies to tissue antigens — heart

AHE

71109

Antibodies to tissue antigens — histone

AHI

71109

Antibodies to tissue antigens — insulin receptor antibodies

INSA

71109

Antibodies to tissue antigens — intercellular cement substance of skin

ICCS

71109

Antibodies to tissue antigens — intrinsic factor

AIF

71109

Antibodies to tissue antigens — islet cell

AIC

71109

Antibodies to tissue antigens — Jo-1

JO1

71119

Antibodies to tissue antigens — keratin

KERA

71119

Antibodies to tissue antigens — liver/kidney microsomes

LKA

71119

Antibodies to tissue antigens — lymphocyte

ALY

71109

Antibodies to tissue antigens — mitochondria

MA

71119

Antibodies to tissue antigens — neuron

ANE

71109

Antibodies to tissue antigens — neutrophil cytoplasm

ANCA

71109

Antibodies to tissue antigens — ovary

AOV

71109

Antibodies to tissue antigens — parathyroid

PTHA

71109

Antibodies to tissue antigens — platelet

APA

71109

Antibodies to tissue antigens — PM-Sc1

PM1

71119

Antibodies to tissue antigens — reticulin

RCA

71119

Antibodies to tissue antigens — salivary gland

ASG

71109

Antibodies to tissue antigens — Scl-70

SCL

71119

Antibodies to tissue antigens — skeletal muscle

SLA

71109

Antibodies to tissue antigens — skin basement membrane

SKA

71109

Antibodies to tissue antigens — smooth muscle

SMA

71119

Antibodies to tissue antigens —thyroglobulin

ATG

71109

Antibodies to tissue antigens —thyroid icrosome

TMA

71109

Antibodies to tissue antigens — TSH receptor antibody test

TSHA

71109

Antibody testing, microbial (see Microbial)

Antigen testing, microbial (see Microbial)

Antithrombin III

ATH

65037

Anus — cytology on specimens from

SMCY

73043

Apolipoprotein B/A1 ratio

APO

66317

Arginine infusion

ARIN

66297

Arsenic

AS

66277

Aspartate aminotransferase

AST

66201

Aspergillus — microbial antibody testing

ASP

69229

Avian precipitins (bird fancier’s disease) — microbial antibody testing

APP

69229

B12 vitamin

RCF

66267

Barbiturate

BARB

66235

Beryllium

BE

66277

Beta-hydroxybutyrate

BHYB

66367

Beta-2-microglobulin

BMIC

66361

Bicarbonate

HCO3

66201

Bilirubin (all fractions)

BILI

66201

Bilirubin (all fractions) — in urine

UBIL

66213

Bilirubin (all fractions) — neonatal

BILN

66365

Bird fancier’s disease

  (see avian precipitins)

Blastomyces — microbial antibody testing

BLM

69229

Bleeding time

BT

65029

Blood — compatibility testing

XMAT

65023

Blood — culture

BC

69215

Blood — faecal occult

FOB

66221

Blood — film

BF

65005

Blood — full examination

FBE

65001

Blood — gases

GAS

66225

Blood — group and blood group antibodies

BGAB

65021

Blood — group antibodies

BGA

65025

Blood — group systems

BGS

65019

Blood — grouping — ABO and RH (D antigen)

BG

65017

Blood — viscosity

VISC

65001

Body cavities, aspirations of — microscopy and culture of material from

MCS3

69209

Body fluids — cytology

BFCY

73045

Bone marrow examination — aspirate

BMEA

65015

Bone marrow examination — Atrephine

BMET

65013

Bordetella pertussis — microbial antibody testing

BOR

69229

Borrelia burgdorferi — microbial antibody testing

BOB

69229

Breath hydrogen test

BHT

66283

Bromide

BRMD

66235

Brucella — microbial antibody testing

BRU

69229

C-l esterase inhibitor — quantitation

CEIQ

66257

C-l esterase inhibitor — functional

CEIF

66258

C-Peptide

CPEP

66405

C-reactive protein

CRP

65001

CA-15.3 antigen

CA15

66261

CA-l9.9 antigen

CA19

66261

CA-125 antigen

C125

66261

Cadmium

CD

66277

Caeruloplasmin

CPLS

66361

Calcitonin

CALT

66405

Calcium (total, dialysed or ionized)

CA

66201

Calculus analysis

CALC

66229

Campylobacter jejuni — microbial antibody testing

CAM

69229

Candida — microbial antibody testing

CAN

69229

Carbamazepine (Tegretol)

CARB

66235

Carboxyhaemoglobin

COHB

65027

Carcinoembryonic antigen

CEA

66261

Cardiac enzymes (see group tests in Division A)

Cardiolipin — tissue antigens — antibodies

ACL

71109

Catecholamines

CAT

66281

Cell mediated immunity — delayed type — hypersensitivity test

CMI

71137

Centromere — tissue antigens — antibodies

ACA

71119

Cervix — cytology — routine

CCR

73053

Cervix — cytology — abnormalities

CCRA

73055

Cervix — microscopy and culture of material from

MCS2

69207

Characterisation of antibodies if positive ENA

ENAP

71103

Chemicals, toxic (ingested or absorbed) — assays

DRGO

66231

Chlamydia — direct detection from clinical material

CHLY

69221

Chlamydia — investigation by cultural methods

CHLC

69261

Chlamydia — investigation by DNA probe

CHLP

69261

Chlamydia — microbial antibody testing

CHL

69229

Chlamydia — microbial antigen testing

CHLY

69221

Chloral hydrate

CHHY

66235

Chlorazepate

CHZP

66235

Chloride

CL

66201

Chloroquine

CLOQ

66235

Chlorpromazine

CHLO

66235

Cholesterol

CHOL

66331

Cholesterol — HDL

HDLC

66317

Cholinesterase

CHSE

66367

Chorionic gonadotrophin — for pregnancy diagnosis

HCG

73527

Chorionic gonadotrophin — for diagnosis of specified conditions

HCGD

73529

Chorionic gonadotrophin — for Down’s syndrome and neural tube defect testing

NTDD

66321

Chromium

CR

66277

Chromosome identification and banding

73287-89

Chromosome identification studies — blood

CSB

73289

Chromosome identification studies — other than blood

CS

73287

Cimetidine

CMTD

66235

Clobazam

CLOB

66235

Clomipramine

CLOM

66235

Clonazepam (Rivotril)

CLON

66235

Clostridium difficile — microbial antigen testing

CLDT

69219

Coagulation — factors (see individual factors)

Coagulation — studies (see group tests in Division A)

Coagulation — time

CT

65029

Coccidioides — microbial antibody testing

CCC

69229

Cold agglutinins

CAG

65005, 65027

Collection of specimen(s) for cytological examination

73051

Compatibility testing

XMAT

65023

Complement, total haemolytic

COM

71081

Complement, total haemolytic — components

C3C3

71083

Complement, total haemolytic — components

C4C4

71083

Complement, total haemolytic — properdin factor

BPFB

71083

Complement, total haemolytic — other components

COMP

71089

Copper

CU

66277

Cortisol

CORT

66405

Coxsackie B1-6 — microbial antibody testing

COX

69229

Creatine kinase

CK

66201

Creatine kinase — isoenzymes

CKI

66201

Creatine kinase — isoenzymes (electrophoresis)

CKIE

66249

Creatinine

C

66201

Cryofibrinogen — qualitative

CFID

66213

Cryofibrinogen — quantitative

CFIE

66215

Cryoglobulins — qualitative

CGLD

66213

Cryoglobulins — quantitative

CGLE

66215

Cryoglobulins — investigation by immunoelectrophoresis or immunofixation

RYO

71061

Cryptococcal antigen — microbial antigen testing

CRYN

69219

Cryptococcus — microbial antibody testing

CRY

69229

CSF — microscopy and culture of material from

MCS3

69209

CSF antigens — group B streptococcus

STB

69219

CSF antigens — Haemophilus influenzae

HI

69219

CSF antigens — Neisseria meningitidis

NMG

69219

CSF antigens — Streptoccus pneumoniae

SPN

69219

Cultural examination of faeces

FCS

69211

Cyclic AMP

CAMP

66405

Cyclosporin

ACLSA

66235

Cystine — qualitative

UCYS

66213

Cystine — quantitative

CYST

66367

Cytology — from body fluids, sputum (1 specimen), urine, washings or brushings

BFCY

73045

Cytology — from cervix — routine

CCR

73053

Cytology — from cervix — Aabnormalities

CCRA

73055

Cytology — from fine needle aspiration of solid tissues

FNCY

73049

Cytology — from fine needle aspiration of solid tissues — aspiration or attendance by a pathologist

FNCP

73051

Cytology — from skin, nipple discharge, lip, mouth, nose or anus

SMCY

73043

Cytology — from vagina

CVO

73057

Cytology — from 3 sputum or urine specimens

SPCY

73047

Cytomegalovirus — microbial antibody testing

CMV

69229

Cytomegalovirus serology in pregnancy — microbial antibody testing

CMVP

69253-57

D-dimer test

DD

65029

D vitamin

VITD

66271

Dehydroepiandrosterone sulphate (DHEAS)

DHEA

66405

Dengue — microbial antibody testing

DEN

69229

11-Deoxycortisol

DCOR

66405

Desipramine

DESI

66235

Dexamethasone

DXST

66295

Dexamethasone — suppression test

DEXA

66295

DHEAS (Dehydroepiandrosterone sulphate)

DHEA

66405

Diazepam

DIAZ

66235

Differential cell count

DIFF

65005

Digoxin

DIG

66235

Dihydrotesterone

DHTS

66405

Diphenylhydantoin (Dilantin)

DIL

66235

Diphtheria — microbial antibody testing

DIPx

69229

Direct Coombs test

CMBS

65005, 65027

Disopyramide (Rythmodan)

DISO

66235

DNA, double-stranded antibodies

DNAD

71099

DNA binding — quantitation and measurement if positive ANA

ANAP

71099

Down’s syndrome and neural tube defects

NTDD

66321

Doxepin hydrochloride

DOXE

66235

Drugs — abuse treatment programme — assay

DATP

66343

Drugs — inappropriate dosage — assay

DRGO

66231

Drugs — therapeutic — assay (see individual drugs)

Dynamic function tests

GHSE

66295

Ear — microscopy and culture of material from

MCS1

69205

Echinococcus — microbial antibody testing

ECC

69229

Echo-coxsackie group — microbial antibody testing

ECH

69229

Electrolytes (see group tests in Division A)

Electron microscopy of biopsy material

EM

72807

Electrophoresis, to demonstrate — creatine kinase isoenzymes

CKIE

66249

Electrophoresis, to demonstrate — lactate dehydrogenase isoenzymes

LDI

66249

Electrophoresis, to demonstrate — lipoprotein subclasses

LEPG

66250

Electrophoresis, to demonstrate — protein classes, or paraprotein

EPP1

66249

Electrophoresis, to demonstrate — protein classes or presence and amount of paraprotein classes, concurrent collection

EPP2

66247

Elements (see individual elements)

Entamoeba histolytica — microbial antibody testing

AMO

69229

Enzyme assays of solid tissue or tissues

ENZS

66285

Epstein Barr virus — microbial antibody testing

EBV

69229

Erythrocyte — assessment of haemolysis

ERYH

65009

Erythrocyte — assessment of metabolic enzymes

ERYM

65009

Erythrocyte — count

RCC

65001

Erythrocyte — sedimentation rate

ESR

65001

Ethosuximide (Zarontin)

ETHO

66235

Euglobulin clot lysis time

ECLT

65037

Extractable nuclear antigens — detection of

antibodies to

ENA

71101

Eye — microscopy and culture of material from

MCS1

69205

Factor II

FII

65045

Factor V

FV

65045

Factor VII

FVII

65045

Factor VIII

VIII

65045

Factor IX

FIX

65045

Factor X

FX

65045

Factor XI

FXI

65045

Factor XII

FXII

65045

Factor XIII

XIII

65045

Factor XIII deficiency test

F13D

65029

Faecal blood

FOB

66221

Faecal fat

FFAT

66283

Faecal fat — haemoglobin — chemical test

FHC

66217

Faecal fat — haemoglobin — immunological test

FHI

66219

Faecal fat — porphyrins — qualitative test

FPR

66217

Faecal fat — reducing substances

FRS

66217

Faeces — culture

FCS

69211

Faeces — microscopy for parasites

OCP

69203

Fatty acids — total free — quantitation

TFFA

66367

Ferritin (see also Iron studies)

FERR

66355

Fibrin monomer

FM

65029

Fibrinogen

FIB

65029

Fibrinogen — degradation products

FDP

65029

Fitzgerald factor

FGF

65045

Flecainide

FLEC

66235

Fletcher factor

FF

65045

Fluorescent treponemal antibody — absorption test (FTA-ABS) — microbial antibody testing

FTA

69229

Fluoxetine

FLUX

66235

Folate — red cell

RCF

66267

Follicle stimulating hormone (FSH)

FSH

66405

Frozen section diagnosis of biopsy material

FS

72803

Fructosamine

FRUC

66201

Full blood examination

FBE

65007

Gamma glutamyl transpeptidase

GGT

66201

Gastric parietal cell — tissue antigens — antibodies

PCA

71119

Gastrin

GAST

66405

Gliadin IgA — tissue antigens — antibodies

GLIA

71119

Globulin

GLOB

66201

Glomerular basement membrane — tissue antigens — antibodies

GBA

71109

Glucagon

GLGO

66405

Glucagon stimulation test

GSTC

66297

Glucose

GLUC

66201

Glucose — tolerance test

GTT

66419

Glycolated haemoglobin (Hb A1c)

GHB

66319

Glycosylated haemoglobin (Hb A1c)

GHB

66319

Gold

AU

66277

Gonadotrophin

GRHS

66297

Group B streptococcus — CSF antigens

STB

69219

Group B streptococcus — microbial antigen testing

STB

69219

Group P9 — simple basic pathology tests

73801-11

Growth hormone

GH

66405

Growth hormone — stimulation by exercise or L-dopa

GHSE

66295

Growth hormone — suppression by dexamethasone or glucose

GHSG

66295

Haematocrit

HCT

65001

Haemoglobin

HB

65001

Haemoglobin — in urine

UHB

66213

Haemoglobinopathy tests

HMGP

65011

Haemophilus influenzae antigens

HI

69219

Haemophilus influenzae — microbial antibody testing

HUS

69229

Haemophilus influenzae — microbial antigen testing

HI

69219

Haloperidol

HALO

66235

Haptoglobins

HGLB

66361

HDL cholesterol

HDLC

66317

Heart — tissue antigens — antibodies

AHE

71109

Heparin — cofactor II

HRNC

65037

Heparin — test

HEPR

65043

Hepatitis delta antibody — anti-delta — microbial antibody testing

HDA

69229

Hepatitis serology — acute hepatitis

HEP

69247

Hepatitis serology — follow-up of proven hepatitis B

HEPB

69249

Hepatitis serology — hepatitis B serology to define immune status

HEP1

69245

Hepatitis serology — hepatitis B surface antigen HBsAg

HBSA

69243

Hepatitis serology — hepatitis

CHEPC

69265

Hepatitis serology — hepatitis delta antibody

HDA

69229

Hepatitis serology — in pregnancy

HEPP

69253-57

Herpes simplex virus — direct detection from clinical material

HSV

69223

Herpes simplex virus — investigation by culture

HSVC

69263

Herpes simplex virus — microbial antibody testing

HPA

69229

Herpes simplex virus — microbial antigen testing

HSV

69223

Heterophile antibodies

IM

65005, 65027

HIAA (hydroxyindoleacetic acid)

HIAA

66367

Histamine

HIAM

66367

Histone — tissue antigens — antibodies

AHI

71109

Histopathology of biopsy material

HIST

72801

Histoplasma — microbial antibody testing

HIP

69229

HLA typing — HLA-B27

HLAB

71147

HLA typing — HLA class 1

HLA1

71149

HLA typing — HLA class 2

HLA2

71151

HMMA (hydroxy-3-methoxymandelic acid, previously known as VMA)

HMMA

66281

HMPG (hydroxy-methoxy-phenylethylene glycol)

HMPG

66281

Homovanillic acid

HVA

66281

Hormone receptor assay — breast

HRA

66315

Hormone receptor assay — ovary

HRO

66315

Hormones — adrenocorticotrophic

ACTH

66405

Hormones — aldosterone

ALDS

66405

Hormones — androstanedione

ANDR

66405

Hormones — C-Peptide

CPEP

66405

Hormones — calcitonin

CALT

66405

Hormones — cortisol

CORT

66405

Hormones — cyclic AMP

CAMP

66405

Hormones — dehydroepiandrosterone sulphate (DHEAS)

DHEA

66405

Hormones — dihydrotestosterone

DHTS

66405

Hormones — follicle stimulating hormone

FSH

66405

Hormones — gastrin

GAST

66405

Hormones — glucagon

GLGO

66405

Hormones — gonadotrophin

GRHS

66297

Hormones — growth hormone

GH

66405

Hormones — growth hormone — stimulation by exercise or L-dopa

GHSE

66295

Hormones — growth hormone — suppression by dexamethasone or glucose

GHSG

66295

Hormones — hormone receptor assay — breast

HRA

66315

Hormones — hormone receptor assay — ovaryH

RO

66315

Hormones — human chorionic gonadotrophin — for pregnancy diagnosis

HCG

73527

Hormones — human chorionic gonadotrophin (see human chorionic gonadotrophin)

Hormones — human placental lactogen

HPL

66373

Hormones — hydroxyprogesterone

OHP

66405

Hormones — insulin

INS

66405

Hormones — insulin, hypoglycaemia test

INHY

66297

Hormones — luteinising hormone

LH

66405

Hormones — oestradiol

E2

66405

Hormones — oestriol

E3

66373

Hormones — oestrone

E1

66405

Hormones — parathyroid hormone

PTH

66405

Hormones — pentagastrin

PSTR

66297

Hormones — progesterone

PROG

66405

Hormones — prolactin

PROL

66405

Hormones — renin

REN

66405

Hormones — sex hormone binding globulin

SHBG

66405

Hormones — somatomedin

SOMA

66405

Hormones — testosterone

TES

66405

Hormones — urine steroid fraction or fractions

USF

66405

Hormones — vasoactive intestinal peptide

VIP

66405

Hormones — vasopressin

ADH

66405

Hormones — 11 deoxycortisol

DCOR

66405

Hormones and hormone binding proteins (see individual hormones and proteins)

66405

Huhner’s test

HT

73521

Human chorionic gonadotrophin — for pregnancy diagnosis

HCG

73527

Human chorionic gonadotrophin — for diagnosis of specified conditions

HCGD

73529

Human chorionic gonadotrophin — for Down’s syndrome and neural tube defect testing

NTDD

66321

Human placental lactogen

HPL

66373

HVA (homovanillic acid)

HVA

66281

Hydatid — microbial antibody testing

HYD

69229

Hydroxy methoxy phenylethylene glycol

HMPG

66281

Hydroxy-3-methoxymandelic acid, previously known as VMA)

HMMA

66281

Hydroxychloroquine

HOCQ

66235

Hydroxyindoleacetic acid

HIAA

66367

Hydroxyprogesterone

OHP

66405

Hydroxyproline

HYDP

66367

ImipramineI

MIP

66235

Immediate frozen-section diagnosis of biopsy material

FS

72803

Immunoglobulins — A

IGA

71067

Immunoglobulins — D

IGD

71067

Immunoglobulins — E (total)

IGE

71075-79

Immunoglobulins — G

IGG

71067

Immunoglobulins — G, 4 subclasses

SIGG

71073

Immunoglobulins — M

IGM

71067

Immunohistochemical investigation of biopsy material

HIS

72805

Infectious mononucleosis

IM

69229

Influenza A — microbial antibody testing

FLA

69229

Influenza B — microbial antibody testing

FLB

69229

Insulin

INS

66405

Insulin — hypoglycaemia test

INHY

66297

Insulin — tissue antigens — antibodies

AINS

71109

Insulin receptor antibodies — tissue antigens — antibodies

INSA

71109

Intercellular cement substance of skin — tissue antigens — antibodies

ICCS

71109

Intestinal disaccharidases

INTD

66283

Intrinsic factor — tissue antigens — antibodies

AIF

71109

Iron studies (iron, transferrin and ferritin)

IS

66263

Islet cell — tissue antigens — antibodies

AIC

71109

Jo-1 — tissue antigens — antibodies

JO1

71119

Keratin — issue antigens — antibodies

KERA

71119

L-dopa

GHLD

66295

Lactate

LACT

66367

Lactate — dehydrogenase

LDH

66201

Lactate — dehydrogenase isoenzymes

LDI

66249

Lamellar body phospholipid

LBPH

66243

Lead

PB

66279

Lecithin/sphingomyelin ratio (amniotic fluid)

LS

66243

Legionella pneumophila — serogroup 1 — microbial antibody testing

LP1

69229

Legionella pneumophila — serogroup 2 — microbial antibody testing

LP2

69229

Leishmaniasis — microbial antibody testing

LEI

69229

Leptospira — microbial antibody testing

LEP

69229

Leucocyte count

WCC

65001

Leucocyte — 3 surface markers — blood, CSF,

serous fluid

LMH

371139

Leucocyte — 3 surface markers — tissue

LMT3

71141

Leucocyte — 6 surface markers — blood, CSF, serous fluid or tissue

LM6

71143

Leucocyte — 6 surface markers — blood, CSF, serous fluid and tissue (s)

LMHT

71145

Lignocaine

LIGN

66235

Lip — cytology on specimens from

SMCY

73043

Lipase

LIP

66201

Lipoprotein electrophoresis

LEPG

66250

Listeria — microbial antibody testing

LIS

69229

Lithium

LI

66201

Liver function tests (see group tests)

LFT

66211

Liver/kidney microsomes — tissue antigens — antibodies

LKA

71119

Lupus anticoagulant

LUPA

65037

Luteinising hormone

LH

66405

Lymphocyte — tissue antigens — antibodies

ALY

71109

Lymphocytes — functional tests — 1 test

LF1

71127

Lymphocytes — functional tests — 2 tests

LF2

71129

Lymphocytes — functional tests — 3 tests

LF3

71131

Magnesium

MG

66201

Mammary serum antigen

MSA

66261

Manganese

MN

66277

Mantoux test

MANT

73811

Measles — microbial antibody testing

MEA

69229

Melanogen (see Urine melanin)

Mercury

HG

66277

Metalbumin detection (Schumm’s test)

SCHM

65027

Metanephrines

MNEP

66281

Methadone

MTDN

66235

Methotrexate

MTTA

66235

MethsuximideM

SUX

66235

Metronidazole

MRDZ

66235

Mexiletine (Mexitil)

MEX

66235

Mianserin

MIAS

66235

Microalbumin

MALB

66361

Microbial antibody testing — actinomycetes

ACT

69229

Microbial antibody testing — adenovirus

ADE

69229

Microbial antibody testing — aspergillus

ASP

69229

Microbial antibody testing — avian precipitins (see avian precipitions)

Microbial antibody testing — Blastomyces

BLM

69229

Microbial antibody testing — Bordetella pertussis

BOR

69229

Microbial antibody testing — Borrelia burgdorferi

BOB

69229

Microbial antibody testing — Brucella

BRU

69229

Microbial antibody testing — Campylobacter jejuni

CAM

69229

Microbial antibody testing — Candida

CAN

69229

Microbial antibody testing — Chlamydia

CHL

69229

Microbial antibody testing — CoccidioidesC

CC

69229

Microbial antibody testing — Coxsackie B1-6

COX

69229

Microbial antibody testing — cryptococcus

CRY

69229

Microbial antibody testing — cytomegalovirus

CMV

69229

Microbial antibody testing — cytomegalovirus serology in pregnancy

CMVP

69253-57

Microbial antibody testing — dengue

DEN

69229

Microbial antibody testing — diphtheria

DIP

69229

Microbial antibody testing— echinococcus

ECC

69299

Microbial antibody testing — echo-coxsackie group

ECH

69229

Microbial antibody testing — Entamoeba histolytica

AMO

69229

Microbial antibody testing — Epstein Barr virus

EBV

69229

Microbial antibody testing — fluorescent treponemal antibody — absorption test (FTA-ABS)

FTA

69229

Microbial antibody testing — Haemophilus influenzae

HUS

69229

Microbial antibody testing — hepatitis C

HEPC

69265

Microbial antibody testing — hepatitis delta antibody—Aanti-delta

HDA

69229

Microbial antibody testing — herpes

HPA

69229

Microbial antibody testing — Histoplasma

HIP

69229

Microbial antibody testing — hydatid

HYD

69229

Microbial antibody testing — infectious mononucleosis

IM

69229

Microbial antibody testing — influenza A

FLA

69229

Microbial antibody testing — influenza B

FLB

69229

Microbial antibody testing — Legionella pneumophila — serogroup 1

LP1

69229

Microbial antibody testing — Legionella pneumophila — serogroup 2

LP2

69229

Microbial antibody testing — leishmaniasis

LEI

69229

Microbial antibody testing — Leptospira

LEP

69229

Microbial antibody testing — Listeria

LIS

69229

Microbial antibody testing — measles

MEA

69229

Microbial antibody testing — Micropolyspora faeni

MIC

69229

Microbial antibody testing — mumps

MUM

69229

Microbial antibody testing — Murray Valley encephalitis

MVE

69229

Microbial antibody testing — Mycoplasma pneumoniae

MYC

69229

Microbial antibody testing — Neisseria menigitidis

MEN

69229

Microbial antibody testing — Newcastle disease

NCD

69229

Microbial antibody testing — parainfluenza 1

PF1

69229

Microbial antibody testing — parainfluenza 2

PF2

69229

Microbial antibody testing — parainfluenza 3

PF3

69229

Microbial antibody testing — paratyphi

PTY

69229

Microbial antibody testing — pertussis

PER

69229

Microbial antibody testing — poliomyelitis

PLO

69229

Microbial antibody testing — Proteus OX 19

POX

69229

Microbial antibody testing — Proteus OXK

POK

69229

Microbial antibody testing — Q fever

QFF

69229

Microbial antibody testing — rapid plasma reagin test

RPR

69229

Microbial antibody testing — respiratory syncytial virus

RSV

69229

Microbial antibody testing — Ross River virus

RRV

69229

Microbial antibody testing — rubella

RUB

69229

Microbial antibody testing — Salmonella typhi (H)

SAH

69229

Microbial antibody testing — Salmonella typhi (O)

SAO

69229

Microbial antibody testing — Schistosoma

STO

69229

Microbial antibody testing — streptococcal serology — anti-DNASE B titre

ADNB

69229

Microbial antibody testing — streptococcal serology — anti-streptolysin O titre

ASOT

69229

Microbial antibody testing — Streptococcus pneumoniae

PCC

69229

Microbial antibody testing — tetanus

TET

69229

Microbial antibody testing — Thermoactinomyces vulgaris

THE

69229

Microbial antibody testing — thermopolyspora

TPS

69229

Microbial antibody testing — Toxocara

TOC

69229

Microbial antibody testing — toxoplasma

TOX

69229

Microbial antibody testing — TPHA (Treponema pallidum haemagglutination test)

TPHA

69229

Microbial antibody testing — trichinosis

TOS

69229

Microbial antibody testing — typhus, Weil-Felix

TYP

69229

Microbial antibody testing — Varicella zoster

VCZ

69229

Microbial antibody testing — VDRL (Venereal Disease Research Laboratory)

VDRL

69229

Microbial antibody testing — Yersinia enterocolitica

YER

69229

Microbial antigen testing — Chlamydia

CHLY

69221

Microbial antigen testing — Clostridium difficile

CLDT

69219

Microbial antigen testing — group B streptococcus

STB

69219

Microbial antigen testing — Haemophilus influenzae

HI

69219

Microbial antigen testing — herpes simplex virus

HSV

69263

Microbial antigen testing — Neisseria gonorrhoeae

GON

69219

Microbial antigen testing — Neisseria meningitidis

NMG

69219

Microbial antigen testing — respiratory syncytial virus

RSVN

69219

Microbial antigen testing — Streptococcus pneumoniae

SPN

69219

Microbial antigen testing — Varicella zoster

VCZN

69219

Micropolyspora faeni

MIC

69229

Microscopic examination of — faeces for parasites

OCP

69203

Microscopic examination of — material other than blood

M

69201

Microscopy and culture of — material from nose, throat, eye or ear

MCS1

69205

Microscopy and culture of — material from skin, superficial sites, urethra, vagina, cervix or rectum

MCS2

69207

Microscopy and culture of — post-op wounds, aspirations of body cavities, synovial fluid, CSF and op/biopsy specimens

MCS3

69209

Microscopy and culture of — specimens of sputum

MCS2

69207

Microscopy and culture of — specimens of sputum, urine or other body fluids for mycobacteria

AFB

69213

Microscopy, culture, identification and sensitivity of urine

UMCS

69217

Mitochondria — tissue antigens — antibodies

MA

71119

Mouth — cytology on specimens from

SMCY

73043

Mucin-like carcinoma-associated antigen

MCA1

66261

Mumps — microbial antibody testing

MUM

69229

Murray Valley encephalitis — microbial antibody testing

MVE

69229

Mycobacteria microscopy and culture of sputum

AFB

69213

Mycoplasma pneumoniae — microbial antibody testing

MYC

69229

Myoglobin in urine

MYU

66213

N-acetyl procainamide

NAPC

66235

Neisseria gonorrhoeae — microbial antigen testing

GON

69219

Neisseria menigitidis antigens

NMG

69219

Neisseria menigitidis — microbial antibody testing

MEN

69229

Neisseria menigitidis — microbial antigen testing

NMG

69219

Neural tube defects and Down’s syndrome

NTDD

66321

Neuron — tissue antigens — antibodies

ANE

71109

Neuron specific enolase

NSEN

66261

Neutrophil cytoplasm — tissue antigens — antibodies

ANCA

71109

Neutrophil functions

NFT

71135

Newcastle disease — microbial antibody testing

NCD

69229

Nickel

NI

66277

Nipple discharge — cytology on specimens from

SMCY

73043

Nitrazepam

NITR

66235

Nordothiepin

NDIP

66235

Norfluoxetine

NFLE

66235

Nortriptyline

NORT

66235

Nose — cytology on specimens from

SMCY

73043

Nose — microscopy and culture of material

MCS1

69205

Nuclear antigens — detection of antibodies to

ANA

71097

Oestradiol

E2

66405

Oestriol

E3

66373

Oestriol — for Down’s syndrome and neural tube defect testing

NTDD

66321

Oestrone

E1

66405

Oligoclonal proteins

OGP

71065

Op/biopsy specimens — microscopy and culture of material from

MCS3

69209

Osmolality — serum or urine

OSML

66223

Ovary — tissue antigens — antibodies

AOV

71109

Oxalate

OXAL

66367

Oxazepam

OXAZ

66235

PAA (phenyl acetic acid)

PAA6

6281

Palmitic acid in amniotic fluid

PALM

66243

Pap smear

CCR

73053

Papanicolaou test

CCR

73053

Paracetamol

PARA

66235

Parainfluenza 1 — microbial antibody testing

PF1

69229

Parainfluenza 2 — microbial antibody testing

PF2

69229

Parainfluenza 3 — microbial antibody testing

PF3

69229

Paraprotein investigation — by electrophoresis

EPPI

66249

Paraprotein investigation — by immunoelectrophoresis or immunofixation

PPRO

71061

Paraprotein investigation — on concurrently collected serum or urine

PPSU

71063

Paraquat

PARQ

66235

Parasites — microscopic examination of faeces

OCP

69203

Parathyroid hormone (PTH)

PTH

66405

Parathyroid — tissue antigens — antibodies

PTHA

71109

Paratyphi — microbial antibody testing

PTY

69229

Partial thromboplastin time

PTT

65029

Passovy factor

PF

65045

Patient episode initiation

PEI

73901-15

Pentagastrin

PSTR

66297

Pentobarbitone

PENT

66235

Perhexiline

PHEX

66235

Pertussis — microbial antibody testing

PER

69229

pH measurement of body fluids other than urine

PH

66213

Phenobarbitone

PHBA

66235

Phensuximide

PHEN

66235

Phenylacetic acid

PAA

66281

Phenytoin

PHEY

66235

Phosphate

PHOS

66201

Phosphatidylglycerol

PTGL

66243

Plasminogen

PLAS

65037

Platelet — aggregation

PLTG

65041

Platelet — count

PLTC

65001

Platelet — tissue antigens — antibodies

APA

71109

PM-Sc1 — tissue antigens — antibodies

PM1

71119

Poliomyelitis — microbial antibody testing

PLO

69229

Porphobilingen in urine

UPG

66213

Porphyrins — quantitative test, 1 or more fractions

PR

66281

Porphyrins in urine — qualitative test

UPR

66213

Potassium

K

66201

Prealbumin

PALB

66361

Prednisolone

PRED

66235

Pregnancy serology — 1 test

MSP1

69253

Pregnancy serology — 2 tests

MSP2

69255

Pregnancy serology — 3 tests

MSP3

69257

Pregnancy testing

73805

Pregnancy testing — diagnosis

HCG

73527

Pregnancy testing — diagnosis of specified conditions

HCGD

73529

Pregnancy testing — for diagnosis of Down’s syndrome and neural tube defect

NTDD

66321

Primidone

PRIM

66235

Procainamide

PCAM

66235

Progesterone

PROG

66405

Prolactin

PROL

66405

Prominal

PROM

66235

Propranolol

PPNO

66235

Prostate specific antigen

PSA

66357

Prostatic acid phosphatase

ACP

66357

Protein — C

PROC

65037

Protein — S

PROS

65037

Protein, quantitation of — alpha fetoprotein

AFP

66353

Protein, quantitation of — alpha fetoprotein — for Down’s syndrome and neural tube defect testing

NTDD

66321

Protein, quantitation of — alpha-l-antitrypsin

AAT

66255

Protein, quantitation of — alpha-2-macroglobulin

AMAC

66255

Protein, quantitation of — beta-2-microglobulin

BMIC

66361

Protein, quantitation of — C-l esterase inhibitor

CEI

66257

Protein, quantitation of — caeruloplasmin

CPLS

66361

Protein, quantitation of — classes by electrophoresis

EPPI

66249

Protein, quantitation of — ferritin (see also Iron studies)

FERR

66355

Protein, quantitation of — haptoglobins

HGLB

66361

Protein, quantitation of — microalbumin

MALB

66361

Protein, total — quantitation of

PROT

66201

Proteus OX 19 — microbial antibody testing

POX

69229

Proteus OXK — microbial antibody testing

POK

69229

Prothrombin time

PT

65029

Pyruvate

PVTE

66367

Q fever — microbial antibody testing

QFF

69229

Quinalbarb

QUIB

66235

Quinidine

QUIN

66235

Quinine

QNN

66235

Rapid plasma reagin test — microbial antibody testing

RPR

69229

RAST

RAST

71079

Rectum — microscopy and culture of material from

MCS2

69207

Red cell folate and serum B12 and serum folate if required

RCF

66267

Red cell porphyrins — qualitative test

RCP

65027

Referred specimen fee

73921

Renin

REN

66405

Respiratory syncytial virus — microbial antibody testing

RSV

69229

Respiratory syncytial virus — microbial antigen testing

RSVN

69219

Reticulin — tissue antigens — antibodies

RCA

71119

Reticulocyte count

RETC

65001

Rheumatoid factor

RF

71106

Rheumatoid factor — quantitation

RFQ

71106

Ross River virus — microbial antibody testing

RRV

69229

RSV (respiratory syncytial virus) — microbial antigen testing

RSVN

69219

RSV (respiratory syncytial virus) — microbial antibody testing

RSV

69229

Rubella — serology

RUB

69229

Salicylate — aspirin

SALI

66235

Salivary gland — tissue antigens — antibodies

ASG

71109

Salmonella typhi (H) — microbial antibody testing

SAH

69229

Salmonella typhi (O) — microbial antibody testing

SAO

69229

Schistosoma — microbial antibody testing

STO

69229

Scl-70 — tissue antigens — antibodies

SCL

71119

Secretin

SSGR

66297

Selenium

SE

66277

Semen examination

SEE

73523

Semen examination — for spermatozoa (post vasectomy)

SES

73521

Serology — in pregnancy (see Pregnancy serology)

Serotonin

5HT

66367

Serum — Bl2

B12

66265

Serum — folate (with Bl2)

FOL

66265

Serum — folate (with Bl2 red cell folate)

RCF

66267

Sex hormone binding globulin

SHBG

66405

Skeletal muscle — tissue antigens — antibodies

SLA

71109

Skin — cytology

SMCY

73043

Skin — microscopy and culture of material from

MCS2

69207

Skin basement membrane — tissue antigens — antibodies

SKA

71109

Snake venom

HISS

66231

Smooth muscle — issue antigens — antibodies

SMA

71119

Sodium

NA

66201

Solid tissue or tissues — chemical assays

ENZS

66285

Solid tissue or tissues — cytology of fine needle aspiration

FNCY

73049

Solid tissue or tissues — cytology of fine needle aspiration by, or in presence of, pathologist

FNCP

73051

Somatomedin

SOMA

66405

Sotalol

SALL

66235

Specific IgG or IgE antibodies

RAST

71079

Specimen referred fee

73921

Sperm antibodies

SAB

73525

Sperm antibodies — penetrating ability

SPA

73525

Sputum — cytology (1 specimen)

BFCY

73045

Sputum — cytology (3 specimens)

SPCY

73047

Sputum — microscopy and culture of specimens

MCS2

69207

Sputum — for mycobacteria

AFB

69213

Stelazine

STEL

66235

Steroid fraction or fractions in urine

USF

66405

Streptococcal serology — anti-DNASE B titre — microbial antibody testing

ADNB

69229

Streptococcal serology — anti-streptolysin O titre — microbial antibody testing

ASOT

69229

Streptococcus — Group B

STB

69219

Streptococcus pneumoniae — antigens

SPN

69219

Streptococcus pneumoniae — microbial antibody testing

PCC

69229

Streptococcus pneumoniae — microbial antigen testing

SPN

69219

Strontium

SR

66277

Sulthiame (Ospolot)

SUL

66235

Synacthen stimulation test

SYNS

66297

Syphilis serology (see group tests)

STS

69231

Testosterone

TES

66405

Tetanus — microbial antibody testing

TET

69229

Thalassaemia studies

TS

65011

Theophylline

THEO

66235

Thermoactinomyces vulgaris — microbial antibody testing

THE

69229

Thermopolyspora — microbial antibody testing

TPS

69229

Thiopentone

TOPO

66235

Thioridazine

THIO

66235

Throat — microscopy and culture of material from

MCS1

69205

Thrombin time

TT

65029

Thyroglobulin

TGL

66261

Thyroglobulin — tissue antigens — antibodies

ATG

71109

Thyroid function tests (including TSH)

TFT

66329

Thyroid stimulating hormone (if requested on its own, or as a preliminary test to thyroid function testing)

TSH

66327

Thyroid stimulating hormone (if requested with other hormones referred to in item 66405))

TSH

66405

Thyroid microsome — tissue antigens — antibodies

TMA

71109

Thyrotrophin releasing hormone test

TRH

66293

Total free fatty acids

TFFA

66367

Total protein

PROT

66201

Toxocara — microbial antibody testing

TOC

69229

Toxoplasma — microbial antibody testing

TOX

69229

TPHA (Treponema pallidum haemagglutination test) — microbial antibody testing

TPHA

69229

Treponema pallidum haemagglutination test — microbial antibody testing

TPHA

69229

Trichinosis — microbial antibody testing

TOS

69229

Triglycerides

TRIG

66331

Trimipramine

TRIM

66235

Tryptic activity in faeces

TAF

66323

TSH receptor antibody test — tissue antigens — antibodies

TSHA

71109

Tuberculosis

MANT

73811

Tumour markers — CA-15.3 antigen

CA15

66261

Tumour markers — CA-19.9 antigen

CA19

66261

Tumour markers — CA-125 antigen

C125

66261

Tumour markers — carcinoembryonic antigen

CEA

66261

Tumour markers — mammary serum antigen

MSA

66261

Tumour markers — mucin-like carcinoma associated antigen

MCA

66261

Tumour markers — neuron specific enolase

NSEN

66261

Tumour markers — prostate specific antigen

PSA

66357

Tumour markers — prostatic acid phosphatase-1 or more fractions

ACP

66357

Tumour markers — thyroglobulin

TGL

66261

Typhus, Weil-Felix — microbial antibody testing

TYP

69229

Urate

URAT

66201

Urea

U

66201

Urea, electrolytes, creatinine (see group tests in Division A)

Urethra — microscopy and culture of material from

MCS2

69207

Urine — bilirubin

UBIL

66213

Urine — catalase test

73805

Urine — cytology — on 1 specimen

BFCY

73045

Urine — cytology — on 3 specimens

SPCY

73047

Urine — cystine (cysteine)

UCYS

66213

Urine — haemoglobin

UHB

66213

Urine — melanin (melanogen)

UML

66213

Urine — microscopy, culture, identification and sensitivity

UMCS

69217

Urine — myoglobin

UMY

66213

Urine — porphobilinogen

UPG

66213

Urine — porphyrins — qualitative test

UPR

66213

Urine — steroid fraction or fractions

USF

66405

Urine — urobilinogen

UUB

66213

Vagina — cytology on specimens from

CVO

73057

Vagina — microscopy and culture of material from

MCS2

69207

Valproate (Epilim)

VALP

66235

Vancomycin

VAN

66235

Varicella zoster — microbial antibody testing

VCZ

69229

Varicella zoster — microbial antigen testing

VCZN

69219

Vasoactive intestinal peptide

VIP

66405

Vasopressin

ADH

66405

VDRL (Venereal Disease Research Laboratory) — microbial antibody testing

VDRL

69229

Viscosity of blood or plasma

VISC

65001

Vitamins — B12

RCF

66267

Vitamins — D

VITD

66271

Vitamins — folate

RCF

66267

Vitamins — quantitation of A, B1, B2, B3, B6, C or E

VIT

66269

VMA (see HMMA)

Von Willebrand’s factor

VWF

65045

Von Willebrand’s factor antigen

VWA

65045

Warfarin

WFR

66235

Xylose

XYL

66367

Yersinia enterocolitica — microbial antibody testing

YER

69229

Zinc

ZN

66367

Notes to the Health Insurance (1995-96 Pathology Services Table) Regulations

Note 1

The Health Insurance (1995-96 Pathology Services Table) Regulations (in force under the Health Insurance Act 1973) as shown in this compilation comprise Statutory Rules 1995 No. 281 amended as indicated in the Tables below.

Table of Statutory Rules

Year and

number

Date of notification

in Gazette

Date of

commencement

Application, saving or

transitional provisions

1995 No. 281

28 Sept 1995

28 Sept 1995

1995 No. 301

26 Oct 1995

1 Nov 1995

—

1996 No. 10

31 Jan 1996

1 Feb 1996

—

1996 No. 54

15 May 1996

1 July 1996

—

1996 No. 232

30 Oct 1996

1 Nov 1996

—

Table of Amendments

    ad. = added or inserted

     am. = amended rep. = repealed rs. = repealed and substituted

Provision affected

How affected

Schedule.................................

am. 1995 No. 301; 1996 Nos. 10 and 54

    
Actions
Download as PDF Download as Word Document
Cases Citing This Decision

0

Cases Cited

0

Statutory Material Cited

0